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Abstract

EPIGENETIC REGULATION OF DRUG METABOLIZING ENZYMES IN
NORMAL AGING
By Mohamad Maher Kronfol, B. Pharm
A dissertation submitted in partial fulfilment of the requirements for the degree of Doctor of
Philosophy at Virginia Commonwealth University.

Virginia Commonwealth University, 2020.
Major Advisor: Joseph L. McClay, Ph.D.
Assistant Professor, Department of Pharmacotherapy and Outcomes Science

Geriatric populations are at a higher risk for adverse drug reactions (ADRs). This may be
partly due to changes in drug metabolism in old age, but the underlying mechanisms are poorly
understood. Prior research in humans and mice has shown age-associated changes to the
expression of several genes involved in drug metabolism. Furthermore, studies of human blood
showed that epigenetic regulation of genes encoding drug metabolizing enzymes change with
age. However, it is unknown if genes in the liver are similarly affected. Therefore, we
hypothesize that genes encoding drug metabolizing enzymes may show differential epigenetic
regulation in the liver with age, and that this will affect rates of drug metabolism.
We selected genes encoding phase I and II drug metabolizing enzymes showing the
strongest evidence of age-related epigenetic changes in prior genome-wide studies of human
blood DNA. We mapped the homologues of these genes in mice and analyzed DNA methylation
and histone acetylation levels in liver samples from aged mice (4, 18, 24 and 32 months) coupled
with functional investigations at those genes. We successfully demonstrated a strong relationship
between DNA methylation and histone acetylation (H3K9ac) levels at cytochrome P450 2E1

xiii

(Cyp2e1) and sulfotransferase family 1A member 1 (Sult1a1) and their expression levels in liver.
Moreover, intrinsic clearance of the CYP2E1 probe drug chlorzoxazone was strongly associated
with DNA methylation and histone acetylation at two regulatory regions of Cyp2e1. Next, we
investigated DNA methylation levels at these genes in peripheral blood and organs like the liver
and the brain. We show that DNA methylation levels of Cyp2e1 and Sult1a1 are substantially
different between blood, liver, and the brain and are correlated to various extents and directions
of effects. Finally, we report an optimized method for genome-wide investigation, Reduced
Representation Bisulfite Sequencing (RRBS), of methylation levels using the innovative
Adaptase technology for utilization in larger aging studies of epigenetics and drug metabolism
by our group in the future. Our successful demonstration of epigenetic control of drug
metabolism in an aged mouse model could pave the way for future clinical studies to develop
epigenetic biomarkers of pharmacokinetic pathways in geriatric patients.

1

Chapter 1: The role of epigenomics in personalized medicine: a literature review
The majority of this chapter was published in
Kronfol MM, Dozmorov MG, Huang R, Slattum PW, McClay JL. The role of epigenomics in personalized
medicine. Expert Rev Precis Med Drug Dev. 2017;2(1):33–45. doi:10.1080/23808993.2017.1284557
Additional excerpts taken from
Kronfol MM, McClay JL (2019) Chapter 14 - Epigenetic biomarkers in personalized medicine. In: Sharma S (ed)
Prognostic Epigenetics. Academic Press, pp 375–395

1.1. Introduction
Personalized medicine is founded upon the concept that individual differences in therapeutic
success are the norm among patients that require pharmacological treatment. This concept is not
new. Hippocrates writing in the 5th century BCE is known to have commented, “give different
ones [drugs] to different patients, for the sweet ones do not benefit everyone, nor do the
astringent ones, nor are all the patients able to drink the same things.” (see Sykiotis et al. 2005).
Thus, the concept of variable response to drugs has been discussed for at least two and a half
millennia. However, being able to predict who will respond to a given drug has proven an
enduring challenge. With the advent of modern genomic technologies, which enable us to read
each patient’s genetic make-up, the idea of personalized medicine is becoming a reality.
Pharmacogenetics, the core discipline of personalized medicine, has already delivered some
profound and meaningful successes. The effectiveness of Cytochrome P450 (CYP450)
genotypes in predicting an individual’s drug metabolizing phenotype is a notable example
(Ingelman-Sundberg 2004a). This has led to several of these biomarkers being approved for
clinical use by regulatory bodies such as the US Food and Drug Administration (FDA)
(www.fda.gov/Drugs/ScienceResearch/ResearchAreas/Pharmacogenetics/ucm083378.htm).
Beyond drug metabolism, genetic variants at numerous other loci have shown robust associations
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indicative of clinical relevance, with commercial kits and services now available to deliver this
information to health providers and consumers (McCarthy et al. 2013).
In the last decade, pharmacogenetics has harnessed the power of genome-wide association
studies (GWAS). This has enabled the field to move beyond the study of candidate genes to
scanning hundreds of thousands of genetic markers for each subject. Several promising new
leads have been discovered. Arguably, however, the success of GWAS in pharmacogenomics
has not mirrored that of complex disease studies. Primarily this may be an issue of statistical
power, whereby the clinical trials necessary to measure drug response are costly and so sample
sizes currently tend to be small. As studies grow in size and number and meta-analyses are
conducted across samples, we can expect GWAS to yield additional insight over time (Ritchie
2012). However, GWAS will not yield all the answers for any given drug response phenotype.
Beyond the limitation where GWAS focuses on common polymorphisms, even if all the relevant
variants for response to a given drug were mapped, we would still be unable to explain all the
phenotypic variation in drug response (Manolio et al. 2009). Drug response is complex and, like
other complex traits, it likely arises from the interplay of multiple genetic and environmental
factors over the life course (Cardon and Harris 2016). DNA sequence is just one component of
this complexity.
Most genotype associations in complex traits such as drug response are probabilistic
indicators of phenotype, which typically say little of certainty about the state of the organism at
the time of sampling. When treating an individual patient with a specific drug, substantial
supporting information in addition to genotype information may be required before making a
clinical decision. Even phenotypes that are strongly influenced by genetics, such as the CYP450
drug metabolism phenotypes, will be modified by the effects of concurrent medications or
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alcohol and tobacco use that may inhibit or interfere with CYP enzyme activity (He et al. 2015;
Tracy et al. 2016). This further illustrates the need to consider information beyond genotype
alone.
There are two broad complexities to living organisms that are not addressed by genotype
information. These are 1) spatial and 2) temporal variation in biological function or phenotypic
expression within the same organism. Consider that humans are composed of multiple cell types
with a diverse array of functions (spatial, or cell-specific variation) and that we take on very
different macroscopic forms in early versus later life (temporal, or developmental variation). Yet
essentially the same genome is present in all nucleated cells at all-time points. In this chapter, we
will show how the processes that lead to cellular diversity and organismal development, i.e.
epigenetics, can be harnessed to provide more nuanced DNA-based biomarkers and novel
treatment strategies (Bock 2009). Indeed, epigenetics may also yield an environmental exposure
record of the patient that we are just beginning to comprehend (Ladd-Acosta 2015). Epigenetic
biomarkers are therefore fundamentally different to studies of gene expression, proteins or
metabolites, which provide snapshots of functional state at a single time point. Epigenetics
provides layers of regulatory and environmental exposure information on top of each
individual’s unique genome (Feinberg 2007). Thus, it indicates what happened to you and you
alone, and from this we may be able to determine your truly personal drug regimen design and
success, disease susceptibility and cure.
1.2. Epigenetics Overview
The term “epigenetics” was first described by the British developmental biologist Conrad
Waddington in the 1940s as “the branch of biology which studies the causal interactions between
genes and their products, which bring the phenotype into being” (Goldberg et al. 2007; Noble
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2015). Waddington’s definition therefore predates the discovery of DNA and so the term
“epigenetics” has developed over time. Waddington was focused on organismal development,
whereby cells starting with the fertilized egg follow trajectories of increasing specialization until
terminal differentiation, which cannot be reversed. One of Waddington’s visual metaphors for
this process, where the cell is conceptualized as a marble rolling down a rolling hillside with
ravines and valleys, has an enduring intuitive appeal and is explained in Figure 1.1.

Figure 1.1. Waddington represented the developmental process as a series of “decisions” made
by differentiating cells that could be represented as forks in the valleys of the “developmental
landscape”. Panels A and B represent the alternate fates of the cell, or ball by analogy. As the
pluripotent stem cell of the egg (ball at the top), begins to specialize, the differentiation
“decisions” made are irreversible. Its pattern of epigenetic regulation is established by the point
of terminal differentiation at the bottom of the landscape. With epigenetic drugs and therapies,
the aim is to artificially reverse maladaptive epigenetic states and essentially “push the ball back
up the hill”. Figure from Noble (2015) (Noble 2015) reproduced with permission.
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Today, backed by knowledge of the genome and some core molecular processes, epigenetics
can be defined as the study of mitotically stable changes in genetic regulation that do not involve
changes to nucleotide sequence (Russo et al. 1996). Mitotic stability, in this sense, means that the
epigenetic state of the parent cell is written to the daughter cell after mitosis, thereby continuing
the developmental trajectory of the parent. This regulation is enacted via epigenetic marks,
which are reversible regulatory modifications to chromatin.
1.2.1. Epigenetic modifications to chromatin
The most intensively studied epigenetic mark is the methylation of DNA cytosine
residues at the carbon 5 position (5mC). This mark is made via the DNA N-methyl transferase
(DNMT) enzymes and is most often found in the sequence context CpG (Irizarry et al. 2009).
DNA methylation is one of the core epigenetic marks essential for regulating gene expression in
normal cell development and differentiation (Reik et al. 2001). While 5mC is the most wellcharacterized, other cytosine modifications have now been discovered, such as 5hydroxymethylcytosine (5hmC), 5-formylcytosine (5fC) and 5-carboxylcytosine (5caC) (Ito et
al. 2011; Bachman et al. 2015). The functions of these exotic marks are still being elucidated, but
5hmC may play an important role in the central nervous system, where it is prevalent, and in the
regulation of pluripotency in stem cells (Kriaucionis and Heintz 2009; Pastor et al. 2011).
Another major class of epigenetic mark involves the post-translational modification of
histones, the proteins that package DNA into nucleosomes (Jenuwein and Allis 2001). Histones
are the chief protein components of chromatin, whereby 146 bp of DNA is wound around each
histone octamer (Luger et al. 1997). There are five major classes of canonical histones, where
each octamer is typically formed of two H2A-H2B dimers and a H3-H4 tetramer while H1
serves as a linker protein between nucleosomes. H3 and H4 have long tails that protrude from the
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nucleosome that can be covalently modified in several places, while other histones can also be
modified to a lesser degree. The best characterized modifications include mono-, di- and trimethylation, acetylation and phosphorylation, although a growing number continue to be
reported (Bannister and Kouzarides 2011). Standard nomenclature abbreviates the histone, the
modified residue and the type of modification, such that histone 3 lysine 27 acetylation is written
as “H3K27Ac”. These modifications are written and erased by specific enzyme families, such as
histone acetyltransferases (HATs) and histone deacetylases (HDACs) in the case of acetylation
marks, or histone methyl transferases (HMTs) and demethylases (HDMs) in the case of
methylation marks (Bannister and Kouzarides 2011).
In addition to histone modifications, histone variants can have significant transcriptional
regulatory roles. Histone variants replace canonical histones to alter nucleosome structure and
ultimately DNA accessibility (Weber and Henikoff 2014). An example histone variant is H2A.Z,
which replaces nucleosomal H2A to perform several complex regulatory roles in gene expression
and development (Marques et al. 2010). Finally, for the purposes of this chapter, we also
mention polycomb epigenetic repressors and bromodomain-containing proteins. Polycomb
proteins can remodel chromatin and typically function as epigenetic gene silencers (Entrevan et
al. 2016), while bromodomain proteins are transducers of the acetylation signal on histones
(Filippakopoulos and Knapp 2014). These chromatin-interacting proteins are relevant for
epigenetic personalized medicine because they are targets for epigenetic drugs that we mention
below in Section 1.3.2. Other putatively epigenetic regulatory mechanisms exist, most notably
the non-coding RNAs (ncRNAs). NcRNAs primarily function as post-transcriptional regulators
of gene expression, but also play roles in regulating chromatin accessibility. They have been
extensively reviewed elsewhere (http://www.cell.com/cell/collections/noncoding-rna).
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1.2.2. Epigenetic effects on gene expression and regulation
The “textbook”, or classic, view of epigenetic regulation is focused on DNA methylation
at gene promoters. In this view, hypomethylated CpGs are typically associated with active,
expressed genes, while hypermethylated CpGs are typically associated with silenced genes. This
effect arises because methylation of cytosine inhibits transcription factor binding (Jaenisch and
Bird 2003). Subsequent research has indicated that methylated cytosine, in addition to
methylated histone H3K9, and deacetylated H3 combine to form a repressive epigenetic
signature, while unmethylated DNA, methylated H3K4, and acetylated H3 combine to form an
activating epigenetic signature (Ivanov et al. 2014), although not all histone modifications are
coupled with DNA methylation (Hansen and Helin 2009). An overview is provided in Figure
1.2. During development, epigenetic patterns change and differentiated cells develop a stable and
unique epigenetic pattern that regulates tissue-specific gene transcription. While this view is
broadly consistent with current findings, waves of new genomic data have yielded a more
nuanced view.
Massive studies such as ENCODE (ENCODE Project Consortium 2012) and Roadmap
Epigenomics (Roadmap Epigenomics Consortium et al. 2015) have significantly advanced our
understanding of genetic and epigenetic regulation. The ENCODE project aims to identify all
functional elements in the genome, while RoadMap Epigenomics aims to elucidate epigenetic
processes that contribute to human biology and disease. Both projects make extensive use of
next-generation sequencing (NGS) to profile reference epigenomes and genome-wide proteinDNA binding patterns, including binding patterns for specific modified histones. The most recent
culmination of these efforts was the publication of 111 reference epigenomes by RoadMap
Epigenomics (Roadmap Epigenomics Consortium et al. 2015). This study revealed epigenetic

8

regulatory modules of coordinated activity, which are specific combinations of DNA
methylation, histone modifications and other proteins that shape chromatin structure, which in
turn determine transcriptional activity. These multi-layer data were used to classify genomic
regions according to functional state (Ernst et al. 2011). The working models produced by
RoadMap Epigenomics include a core 15 chromatin state model (Roadmap Epigenomics
Consortium et al. 2015) and an expanded 18 chromatin state model
(http://egg2.wustl.edu/roadmap/web_portal/chr_state_learning.html), the latter including twelve
active and six inactive states. Active states include transcribed regions, active transcription start
sites and their flanking regions, active enhancers and zinc finger protein binding sites. Inactive
states include heterochromatin and repressed polycomb regions. This model, although complex,
has already proven powerful for understanding regulation of gene expression.(Consortium 2015;
Aguet et al. 2017)
1.2.3. Individual differences in epigenetic states and developmental plasticity
Epigenetic modifications to chromatin are affected by exposure to environmental factors,
and any changes so induced are inherited mitotically in somatic cells (Feinberg 2007). Studies in
human twins have shown that, while their epigenomes are very similar in early life, they diverge
as the twins become older as a result of differing environmental exposures across the life course,
in addition to stochastic effects (Fraga et al. 2005). Epigenetic changes in response to
environmental factors may have evolved to provide plasticity in adaptation to environmental
cues (Feinberg 2007). Through the phenomena of de novo epigenetic writing and mitotic
stability, the effects of environmental factors can become embedded in the genome and persist to
produce long-term phenotypic changes (Feil and Fraga 2012). Example environmental factors
with demonstrated developmental consequences include diet, toxins and stress. There is
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increasing recognition of the importance of this phenomenon for epigenetic translational
research, because it provides concrete biological pathways that are involved in the persistence of
environmental effects (Rutter 2016).
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Figure 1.2. Epigenetic regulation of gene expression via chromatin remodeling. The diagram
shows two generic chromatin activity states. At the top, active chromatin is open and accessible
to transcription factors and polymerases, with nucleosomes spread apart, DNA typically in an
unmethylated state and acetylation marks on histones. HAT is histone acetyltransferase,
SWI/SNF is a nucleosome remodeling complex, RNA Pol II is RNA polymerase II. The lower
panel shows the opposite inactive chromatin scenario, where the nucleosomes are tightly packed,
the DNA is methylated and inaccessible to transcription factors, while histones have their
acetylation marks removed. HDAC is histone deacetylase, HMT is histone methyltransferase.
Figure is adapted from Luong, P. Basic Principles of Genetics, Connexions Web site.
[http://cnx.org/content/m26565/1.1/] (2009) under a Creative Commons Attribution License
([http://creativecommons.org/licenses/by/3.0/CC-BY 3.0]).
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Epigenetic states can also vary between individuals because of genetic differences. In the
case of methylation, one of the simplest examples involves polymorphic CpG sites (Zhi et al.
2013). If a nucleotide substitution ablates a CpG in some individuals, those individuals cannot be
methylated at that locus. There are several examples of disease-associated polymorphic CpGs,
suggesting that this is a significant contributor to individual differences in disease risk (Cazaly et
al. 2015; Zhou et al. 2015). In addition to polymorphic CpGs, DNA sequence variation may also
affect the binding of chromatin-interacting proteins and thus influence epigenetic states (McClay
et al. 2015). Thus, individual differences in epigenetic states, whether arising via genotype or
maladaptive responses to environmental factors, can lead to disease.
1.3. Epigenetic Applications in Personalized Medicine
Epigenetic disease associations provide not only mechanistic clues to disease etiology but
can also function as diagnostic biomarkers. The developmental stage- and tissue-specificity of
epigenetic marks has led to considerable interest in developing biomarkers that capitalize on
these unique properties (García-Giménez 2015). Furthermore, the fact that epigenetic marks are
reversible has led to significant interest in the development of drugs with epigenetic modes of
action (Szyf 2009; Hunter 2015).
1.3.1. Epigenetic biomarkers of disease
The largest body of work in disease epigenetics to date is on cancer. Since the first links
between DNA methylation and cancer were established in the early 1980s, a number of
epigenetic findings have been described, implicating several aspects of the epigenetic machinery.
Some excellent reviews of cancer epigenetics have been published recently (Suvà et al. 2013;
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Feinberg et al. 2016), so here we limit ourselves to epigenetic marks in cancer showing evidence
or potential as diagnostic or prognostic biomarkers.
Current epigenetic biomarker applications predominantly involve DNA methylation
(Amacher 2016). In the United States, nucleic acid-based tests intended for general clinical use
are regulated by the Food and Drug Administration (FDA) as medical devices. Currently there
are no FDA-approved tests that rely exclusively on epigenetic biomarkers. However, one
commercially available test with an epigenetic component has received full FDA approval. This
is ColoGuard®, a screening test for colorectal cancer in adults over 50. The test uses DNA
methylation levels at BMP3 and NDRG4, in combination of mutated KRAS and an
immunochemical assay for hemoglobin (Table 1.1). This test was reported to have superior
sensitivity but slightly lower specificity for colorectal cancer compared to the traditional
screening method, fecal immunochemical testing (FIT) (Imperiale et al. 2014). However, more
recent results suggest FIT may be more effective and less costly than ColoGuard®, the latter
necessitating either very high patient uptake or a 60% reduction in cost per test to become the
preferred testing method (Ladabaum and Mannalithara 2016). This illustrates the economic
barriers that diagnostic tests must overcome, beyond the demonstration of efficacy and
reproducibility, in order to become widespread.
Two other epigenetic tests are currently available in the US, classified as Laboratory
Developed Tests (LDTs) and regulated under the Clinical Laboratory Improvement Amendments
(CLIA) program. This means that the test may only be conducted “in house” in the laboratory
where it was developed, once the lab meets CLIA performance standards. The two tests are
ConfirmMDx and AssureMDx, for prostate cancer and bladder cancer respectively.
Hypermethylation of the glutathione S-transferase gene (GSTP1) promoter in prostate cancer
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was first shown in the 1990s (Lee et al. 1994). This marker, plus APC and RASSF1, are now
components of the ConfirmMDx test (Table 1.1), which is used to address false-negative
prostate biopsy concerns (Partin et al. 2014). The AssureMDx test for bladder cancer involves
the analysis of DNA methylation levels of three genes (TWIST1, ONECUT2 and OTX1) in
combination with mutation analysis of three others (van Kessel et al. 2016).
In lung cancer, the DNA methylation of the SHOX2 gene was reported to be an accurate
marker for identifying lung cancer based on analysis of bronchial aspirates (Schmidt et al. 2010).
In Europe, this biomarker is now commercially available as the Epi proLungVR BL Reflex
Assay (Dietrich et al. 2012). However, this test has not yet received regulatory approval for use
in the USA.

Product

Proprietor/
Launch year

Specimen

Colorectal
cancer

Stool

ConfirmMDx MDxHealth/2012

Prostate
cancer

Tissue

AssureMDx

Bladder
cancer

Urine

Cologuard

Exact
sciences/2014

Disease

MDxHealth/2016

Epigenetic Targets
DNA methylation
of NDRG4 and
BMP3 (plus other
genetic markers)
DNA
methylation of
GSTP1, RASSF1
and APC.
DNA methylation
of TWIST,
ONECUT2 and
OTX1 (plus other
genetic markers)

Table 1.1. Commercially available epigenetic diagnostic tests in the United States.

Regulation

FDA

LDT/CLIA

LDT/CLIA
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In breast and ovarian cancer, hypermethylation of the BRCA1 promoter region has been
observed repeatedly (Cancer Genome Atlas Research Network 2011; Stefansson and Esteller
2013). BRCA1 is also thought to epigenetically repress expression of the oncogenic microRNA
miR-155 via a mechanism involving histone deacetylase 2 (HDAC2) (Chang et al. 2011). A
recent study by Anjum et al. (2014) identified a blood cell DNA methylation signature at BRCA1
that was able to predict breast cancer risk several years prior to diagnosis (Anjum et al. 2014).
However, this biomarker is not yet available in a commercial kit or test.
The biomarker potential of circulating cell-free DNA (cfDNA) has been investigated in
breast cancer and other cancers. Circulating cfDNA is extracted from plasma or serum and is
derived from dying tumor cells that release their DNA into the bloodstream. Kloten et al (2013)
used a panel of three genes (ITIH5, DKK3 and RASSF1A) that showed hypermethylation in
serum cfDNA from breast cancer patients and found these could discriminate between patients
and controls with a sensitivity of 67% and specificity of 69% (Kloten et al. 2013). Fackler et al.
(2014) followed this with a panel of 10 genes and cancer-specific DNA was detected in sera with
a sensitivity of 91% and specificity of 96% in the test samples (Fackler et al. 2014). The
researchers of the latter study are reportedly working with the diagnostics company Cepheid to
bring this test to market (Butkus).
While epigenetic studies of cancer are arguably the most advanced relative to other areas,
several diseases have shown promising findings, particularly with respect to DNA methylation.
These include neurological disorders such as Alzheimer’s Disease (De Jager et al. 2014; Lunnon
et al. 2014) and Parkinson’s Disease (Jowaed et al. 2010), autoimmune disorders such as
systemic lupus erythematosus (Absher et al. 2013), and psychiatric disorders such as
schizophrenia (Pidsley et al. 2014; Aberg et al. 2014) and autism (Ladd-Acosta 2015). Despite
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these advances, there are no currently available diagnostic kits for these diseases that employ
epigenetic markers. Nevertheless, it is hoped that the clinical value of epigenomics already seen
in oncology will be replicated in these areas (Heyn and Esteller 2012).
1.3.2. Epigenetic drugs
The dynamic and reversible nature of epigenetic modifications is of particular relevance
to drug development, as it implies that specific disease-associated epigenetic states may be
reversible with pharmacological treatment (DeWoskin and Million 2013). This segment will
summarize current and potential “epidrugs”, or drugs with epigenetic modes of action. Epidrugs
are classified according to their respective target enzymes, and include the following: DNA Nmethyl transferase inhibitors (DNMTi), histone acetyltransferase inhibitors (HATi/KATi),
histone methyltransferase inhibitors (HMTi/KMTi), histone N-methyl lysine demethylase
inhibitors (HDMi/KDMi), histone deacetylase inhibitors (HDACi/KDACi), and bromodomain
inhibitors. As of 2019, there are two classes of epigenetic drugs that have been approved by FDA
for clinical use in the United States: DNMTi and HDACi (see Table 1.2).
The first approved epidrug in the US was azacitidine (Vidaza, Azadine), a DNMTi
indicated to treat chronic myelomonocytic leukemia and myelodysplastic syndrome. Azacitidine
was approved in 2004 and quickly followed by decitabine (Dacogen) with same indication two
years later. Both drugs cause broad hypomethylation that leads to cellular dysregulation that
most seriously affects rapidly dividing cells. It is important to note that these drugs are not highly
locus-specific and these agents can cause hypomethylation at many genomic sites. Even though
current drugs are designed to favorably induce genes that have been silenced in cancer (Liang et
al. 2002), they may also activate the expression of prometastatic genes as well as oncogenes
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(Cheishvili et al. 2015). There remains a need to develop more selective DNMTi to improve the
efficacy and reduce side effects for this class of drug.
The potential application of DNMTi to other diseases is also under investigation and
examples include multiple sclerosis (Peedicayil 2016), HIV (Abdel-Hameed et al. 2016), pain
(Sun et al. 2015) and memory (Singh et al. 2015). For example, DNMT activity was observed in
HIV-1 infection of CD4(+) T-cells in vitro and induced hypermethylation of distinct cellular
promoters (Abdel-Hameed et al. 2016). Studies from Rajasethupathy et al. suggested that DNA
methylation is necessary for serotonin-dependent long-term facilitation in memory formation
(Rajasethupathy et al. 2012). For a curative therapy of AIDS patients, a combination of
antiretroviral drugs and epidrugs has been suggested for the reactivation of latent HIV-1
genomes. These epidrugs include DNMTi, HDACi, histone methyltransferase inhibitors (HMTi)
and histone demethylase inhibitors (Abdel-Hameed et al. 2016).
The HDAC inhibitors suberoylanilide hydroxamic acid (SAHA, vorinostat, in 2006) and
romidepsin (depsipeptide, in 2009) have proven to be successful in cancer therapeutics (Lane and
Chabner 2009). These agents cause the accumulation of acetylated histones and prevent
progression of tumor cells. Vorinostat was the first HDACi to be approved by the FDA,
indicated for cutaneous manifestations in patients with cutaneous T-cell lymphoma (CTCL).
Panobinostat is the latest HDACi approved by the FDA in 2015 and is indicated for the treatment
of multiple myeloma in combination with bortezomib and dexamethasone. Outside the US,
HDACi approvals vary.
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Mechanism of Action

DNA N-Methyltransferase
Inhibitor (DNMTi)

Histone Deacetylase
inhibitors (HDACi)

Active Ingredient
(Trade name®,
Proprietor)

Date of
Approval

Azacitidine
(Vidaza®, Celgene)

May 19,
2004

Decitabine
(Dacogen®, Otsuka)

May 2, 2006

Vorinostat
(Zolinza®, Merck)

October 6,
2006

Romidepsin
(Istodax®, Celgene)

November
5,2009

Belinostat
(Beleodaq®, Spectrum
Pharmaceuticals)

July 3, 2014

Panobinostat
(Farydak®, Novartis)

February 23,
2015

Indication(s)
Chronic Myelomonocytic
Leukemia. Myelodysplastic
Syndrome i.
Chronic Myelomonocytic
Leukemia. Myelodysplastic
Syndromes ii.
Cutaneous manifestations
in patients with cutaneous
T-Cell Lymphoma (CTCL)
who have progressive,
persistent or recurrent
disease on or following two
systemic therapies.
Cutaneous T-cell
Lymphoma (CTCL) iii,
Peripheral T-cell
Lymphoma (PTCL) iii
Relapsed or Refractory
Peripheral T-cell
Lymphoma (PTCL)
Multiple Myeloma after
receiving at least 2 prior
regimens, including
bortezomib and an
immunomodulatory agent iv

Table 1.2. Classification of US FDA-approved epigenetic drug classes according to mechanism of action.
i

Subtypes: refractory anemia or refractory anemia with ringed sideroblasts (if accompanied by

neutropenia or thrombocytopenia or requiring transfusions), refractory anemia with excess blasts,
refractory anemia with excess blasts in transformation.

ii

Including 90 previously treated and

untreated, de novo and secondary MDS of all French-American-British subtypes 91 (refractory
anemia, refractory anemia with ringed sideroblasts, refractory anemia with excess blasts, 92
refractory anemia with excess blasts in transformation, and 93 intermediate-1, intermediate-2, and
high-risk International Prognostic Scoring System groups).iii In patients who have received at least
one prior systemic therapy.iv In combination with bortezomib and dexamethasone.
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In Europe, for example, only panobinostat has been approved for general clinical use (to
treat multiple myeloma), while belinostat received orphan designation for peripheral T-cell
lymphoma (PTCL). In China, an additional HDACi known as chidamide (Epidaza®), was
approved for treatment of PTCL by the Chinese FDA in 2015. Although most HDACi are
approved for cancer type indications, studies have suggested potential roles in schizophrenia
(Kurita et al. 2012) and Type2 diabetes (Sharma and Taliyan 2016). However, similar to the
DNMTi drugs, current HDACi have broad effects across the genome and lack locus-specificity.
These drugs can have serious side effects (Hunter 2015) and use of currently approved HDACi
in cancer is often indicated only after other treatments have failed, or as combination therapies
(Table 1.2).
Besides these two approved epidrug classes, HMTi and bromodomain inhibitors are other
emerging epidrug classes under development. Pinometostat is a small molecule inhibitor of the
histone methyltransferase DOT1L for the treatment of MLL-r leukemia (Daigle et al. 2013).
Tazemetostat is an orally administered, first-in-class small molecule HMTi that targets the EZH2
transcriptional repressor to treat multiple types of hematological malignancies and genetically
defined solid tumors (Kurmasheva et al. 2017). GSK3326595, an inhibitor of the transcriptional
regulator protein arginine methyltransferase 5 (PRMT5), is also in phase 1 clinical trial.
Bromodomain proteins are readers that recognize acetylated lysine and transduce the gene
activation signal (Filippakopoulos and Knapp 2014). OTX-015 and CPI-0610 are bromodomain
protein inhibitors both in phase I trials for cancers. These drugs target a specific family of
bromodomain proteins, known as Bromodomain Extra-Terminal motif (BET) proteins (Chung et
al. 2011). Another BET inhibitor, Apabetalone (RVX-208), is in Phase III clinical trials for
cardiovascular events in Type 2 diabetes subjects with coronary artery disease. These example
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epidrugs, and several more are advancing through the clinical trial pipeline, are summarized in
Table 1.3. In this table, we focus only on epidrugs in active or planned clinical trials registered
in the US (clinicaltrials.gov) and show the latest phase trial for each drug, plus any trials for
indications outside oncology. We restrict our listing of early phase cancer indications because
these are too numerous to list concisely.
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Mechanism of action

BET Bromodomain Inhibitors

Active ingredient (Proprietor)

Indication

Clinical
Trial Phase

Trial
Ref ID

Apabetalone/
RVX-208
(Resverlogix)

High-risk type 2 diabetes
mellitus with coronary artery
disease

Phase III

NCT02586155

CPI-0610 (Constellation
Pharmaceuticals)

Malignant Peripheral Nerve
Sheath Tumor

Phase II

INCB054329 (Incyte)

Advanced malignancies

Phase I/II

NCT02431260

GSK525762
(GlaxoSmithKline)

Carcinoma and hematological
malignancies

Phase I

NCT01587703,
NCT01943851

GSK2820151
(GlaxoSmithKline)

Advanced or recurrent solid
tumors

Phase I

NCT02630251

ZEN-3694
(Zenith Epigenetics)

Metastatic castration-resistant
prostate cancer (mCRPC) i

Phase I

NCT02711956i,
NCT02705469

OTX015/MK-8628 (Merck)

Selected advanced solid
tumors

Phase I

NCT02698176

TEN-010/ RO6870810
(Hoffmann-La Roche)

Advanced Solid Tumors;
Acute Myeloid Leukemia

Phase I

NCT01987362,
NCT02308761

FT-1101
(Forma therapeutics)

Relapsed/Refractory Acute
Leukemia

Phase I

NCT02543879

BMS-986158 (Bristol-Myers
Squibb)

Advanced Solid Tumors

Phase I

NCT02419417

Mivebresib/ABBV-075
(AbbVie)

Advanced cancers

Phase I

NCT02391480

NCT02986919
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DNA N-Methyltransferase Inhibitor
(DNMTi)

Non-Selective

Histone Deacetylase
inhibitors (HDACi)

Guadecitabine (Astex)

Acute Myeloid Leukemia

Phase III

NCT02920008

TdCyd
(NCI)

Advanced Solid Tumors

Phase I

NCT02423057

Advanced Hormone Receptor
positive (HR+) Breast Cancer

Phase III

NCT02115282

Entinostat
(Syndax)

ii

Givinostat/ITF2357
(Italfarmaco)

Chronic Myeloproliferative
Neoplasms

Phase II

NCT01761968

Resminostat
(4SC AG)

Advanced Stage Mycosis
Fungoides or Sézary
Syndrome

Phase II

NCT02953301

Quisinostat/JNJ-26481585
(Janssen)

Ovarian cancer iii

Phase II

NCT02948075

Pracinostat/SB939 (NCIC
Clinical Trials Group)

Acute Myeloid Leukemia iv,
Myelofibrosis v

Phase II

NCT01912274iv
NCT02267278v

Tefinostat
(Chroma)

Hepatocellular Carcinoma

Phase I/II

NCT02759601

AR-42
(Celgene)

Relapsed multiple myeloma vi

Phase I

NCT02569320

CUDC-907
(Curis)

Multiple Myeloma

Phase I

NCT01742988

Phase II

NCT02954991

Phase I

NCT02635061

HDAC 1&4
Selective

Mocetinostat
(Mirati)

Non-Small Cell Lung Cancer

HDAC 6
Selective

ACY 241
(Acetylon)

Non-Small Cell Lung Cancer

vii

vii
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Histone Lysine Demethylases
(KDM/HDM)

LSD1
inhibitors

DOT1L
inhibitor
Histone Lysine
Methyl Transferase
(KMT/HMT)

EZH1/2
inhibitor
EZH2 inhibitor

PRMT5
inhibitor

KA2507
(Karus)

Solid tumor

Phase I

GSK2879552
(GlaxoSmithKline)

Myelodysplastic Syndrome

Phase II

Tranylcypromine (Martin Luther
Universität)

Relapsed/Refractory Acute
Myeloid Leukemia viii

Phase I/II

NCT02261779

INCB059872
(Incyte)

Advanced Malignancies

Phase
I/II

NCT02712905

IMG-7289
(Imago BioSciences)

Acute Myeloid Leukemia

Phase I

NCT02842827

Pinometostat/
EPZ-5676
(Epizyme)

Relapsed/Refractory
Leukemias ix

Phase I

NCT03008018
NCT02929498

NCT01684150

DS-3201b
(Daiichi Sankyo)
Tazemetostat/
EPZ-6438
(Epizyme)
MAK683
(Novartis)

Lymphomas

Phase I

NCT02732275

Advanced Solid Tumors or
B-cell lymphomas

Phase I/II

NCT01897571

Diffuse Large B-cell
Lymphoma

Phase I/II

NCT02900651

GSK2816126
(GlaxoSmithKline)

Lymphomas, Multiple
Myeloma, Solid Tumors

Phase I

NCT02082977

GSK3326595
(GlaxoSmithKline)

Solid Tumors and NonHodgkin’s Lymphoma

Phase I

NCT02783300

Table 1.3. Classification of epigenetic drug classes in active clinical trials registered in the US (clinicaltrials.gov) according to mechanism of action.
i

In combination with Enzalutamide.
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ii

In combination with Aromasin (Exemestene).
In combination with Paclitaxel and Carboplatin chemotherapy.
iv
In combination with Azacitidine.
v
In combination with Ruxolitinib.
vi
In combination with Pomalidomide.
vii
In Combination with Nivolumab.
viii
In combination with all-trans-retinoic acid (ATRA) chemotherapy.
ix
Only patients with rearrangements involving the MLL gene.
iii

LSD1: Lysine (K)-specific demethylase 1A, DOT1L: Disruptor of telomeric silencing 1-like, EZH1 or EZH2: Enhancer Of Zeste
Homolog 1 or 2 Polycomb Respressive Complex 2 Subunit, PRMT5: Protein Arginine Methyl Transferase 5.
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Finally, several HATi are in preclinical studies at time of writing. Aberrant function of
HATs, also called lysine acetyltransferases (KATs), is correlated with cancer and other diseases
(Khan and Khan 2010). HATi are great candidates with potential therapeutic utility, but current
HATi only have moderate potency and specificity and none are in clinical trial at time of writing.
Nevertheless, some HATi have shown efficacy in preclinical studies. Compound C646 is a
pyrazolone-containing small molecule inhibitor of the p300/CBP HAT subfamily (Bowers et al.
2010). It has been shown to cause growth arrest in melanoma cell lines and inhibit cancer cell
growth in prostate and lung cancer cell lines. PU139 is a pyridoisothiazolone that inhibits several
HAT subfamilies and was shown to block neuroblastoma xenograft growth in mice (Gajer et al.
2015). These agents and others in development are indicative that HATi are still in infancy
relative to other epigenetic drugs, but they show enormous promise and need further investment
to reach their potential as therapeutic compounds.
1.3.3. Epigenetic biomarkers of drug response
As a natural extension of pharmacogenetics, it is possible to use epigenetic biomarkers to
predict drug response. While none have yet achieved regulatory approval for clinical use, a small
number of examples are established in the literature. Among the best known is DNA methylation
of the MGMT promoter. This gene encodes a DNA repair enzyme (O6-alkylguanine DNA
alkyltransferase). Methylation in the promoter region of MGMT is associated with better
response to alkylating neoplastic agents like temozolomide, as first shown in glioblastoma by
Esteller et al. (2000) (Esteller et al. 2000) and later by Hegi et al. (2005) (Hegi et al. 2005). The
mechanism of effect is as follows. Temozolamide alkylates or methylates DNA at the N-7 or O-6
positions of guanine residues and the resulting DNA damage triggers tumor cell death.
Hypomethylation of MGMT leads to expression of O6-alkylguanine DNA alkyltransferase,
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which can repair the DNA damage, whereas hypermethylation leads to silencing of the gene and
thus greater susceptibility to the drug (Figure 1.3). In addition to glioma, a role for MGMT in
predicting response to metastatic colorectal cancer (mCRC) treatment has also been suggested
(Fornaro et al. 2016).

Figure 1.3. MGMT: O-6-methylguanine-DNA methyltransferase. The MGMT enzyme repairs
tumor DNA damage induced by the anticancer drug temozolomide. However, if the MGMT gene
is methylated and not expressed, the DNA damage cannot be adequately repaired leading to
greater tumor sensitivity to temozolomide and a better clinical response. Adapted from (Kronfol
and McClay 2019).

Other published epigenetic biomarker examples include GSTP1 and BRCA1. Methylation
of the promoter of GSTP1 is correlated with survival in breast cancer patients and may be
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predictive of treatment efficacy with doxorubicin (Chiam et al. 2011) or DNA methyltransferase
(DNMT) inhibitors (Dejeux et al. 2010). The BRCA1 gene plays a role in DNA damage response
and hypermethylation of the BRCA1 promoter region may be predictive of enhanced sensitivity
to platinum-derived drugs in cancer cell lines and xenografted tumors; it also may be predictive
of increased time to relapse and survival in ovarian cancer patients under cisplatin treatment
(Stefansson et al. 2012).
The impact of epigenetics in drug response has been investigated beyond oncology. For
example, methylation of the P2 promoter of the IGF1 gene affects transcriptional response to
growth hormone (GH) (Ouni et al. 2016). GH is mainly used to treat children with short stature
due to growth hormone deficiency. Ouni et al. (Ouni et al. 2016) measured P2-driven and total
IGF1 transcripts before and 12 h after the GH injection and found an increase in P2-driven
transcripts with a very strong inverse correlation with CG-137 methylation. This correlation
accounted for ~ 25% of the variability in the response to GH.
1.3.4. Epigenetic modification of drug absorption, distribution, metabolism and excretion
(ADME) genes
ADME genes encode transporters, plasma proteins, and drug metabolizing enzymes that
are responsible for absorption, distribution, metabolism and excretion of xenobiotics. Genetic
variation at ADME genes has proven extremely successful in predicting individual differences in
pharmacokinetics, particularly in the case of drug metabolizing phenotypes associated with the
CYP450s, as mentioned above. However, there remain large individual differences in drug
metabolism unexplained by genetic variation that have led to the suggestion that epigenetics may
substantially influence these phenotypes (Ivanov et al. 2012). Unfortunately, research to date has
not yet directly addressed this question, but individual variation in epigenetic states of ADME
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genes has been correlated with a range of outcomes. For example, Parkinson’s disease has been
associated with hypomethylation of the CYP2E1 gene promoter in the brain (Kaut et al. 2012).
Methylation levels at CYP1B1 (Tokizane et al. 2005) and CYP1A1 (Okino et al. 2006) have been
associated with prostate cancer, and CYP2W1 with colon cancer (Gomez et al. 2007).
Methylation levels at the drug transporter genes OCT1 (Schaeffeler et al. 2011) and OCT2 (Liu
et al. 2016), responsible for the renal excretion of drugs, have been associated with renal
carcinoma. These findings demonstrate the existence of inter-patient variability in ADME gene
epigenetic states, some of which have functional effects on gene expression. However, the extent
of normal epigenetic variation at these loci in the population and the extent to which it will affect
pharmacokinetic phenotypes remains to be determined.
1.4. Aging
1.4.1. Aging, drug response, and adverse drug reactions
The elderly population in the U.S comprises 15% of the total population, which translates
to 49 million Americans aged 65 or older in 2016. This number is projected to increase to 56
million in 2020. The older adult population has a higher mean healthcare expenditure per annum
($5,994) than that of the rest of the population ($4,612). It is estimated that 40% of persons 65
years of age or older take five to nine medications concurrently, while almost one fifth (18%)
take 10 or more. Ultimately, older adults are almost seven times as likely as younger persons to
have adverse drug reactions (ADRs) that require hospitalization (Budnitz et al. 2006). The high
level of drug intake associated with older age makes older adults particularly vulnerable to
ADRs, but there is strong potential to improve this situation because 80 percent of ADRs in this
population are dose-related and thus preventable (Routledge et al. 2004). Alleviation of dose
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related ADRs for the aging population would be advantageous for managing this population’s
pharmacological interventions and improve their health.
1.4.2. Personalized dosing in the elderly population
Age-related changes to drug response are multifactorial in origin (McLachlan et al. 2009). First,
aging effects on renal and hepatic function alter drug pharmacokinetics (PK) and
pharmacodynamics (PD), but these functions are considered too coarse to guide dosing because
they do not capture specific changes to drug metabolizing enzymes (Butler and Begg 2008;
McLachlan and Pont 2012; Tan et al. 2015). Second, despite significant successes in several
areas, particularly in oncology, genetic tools are insufficient to bring about optimal drug therapy
in all instances (Roses 2000). Genotype-based markers are of limited utility to explain intraindividual changes in drug response with age because they are invariant across lifespan.
Therefore, to enable personalization of dosing in older adults, new markers of determinants of
drug metabolism are needed (McLachlan and Pont 2012)
1.4.3. Epigenetics of Aging
The most well studied epigenetic modification is the methylation of carbon 5 of cytosines
at cytosine-guanine dinucleotide (CpG) positions, termed 5-methylcytosine (5mC). A haploid
human genome has around 28 million CpGs, or 1% of total sequence (Jabbari and Bernardi
2004; Babenko et al. 2017). Global 5mC, or the aggregate measure of all the 5mC in the
genome, has been consistently reported to decrease with age in humans (Gonzalo 2010;
Unnikrishnan et al. 2018). However, studies with the ability to measure site-specific methylation
revealed hypermethylation at some gene promoters in older persons indicating that some loci
gain methylation while others either lose methylation or remain unchanged with age
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(Unnikrishnan et al.; Fraga and Esteller 2007; Fraga 2009). Those genomic regions displaying
changes with age, regardless of the direction of effect, subsequently came to be known as ageassociated differentially methylated regions (a-DMRs) (Bjornsson et al. 2008; Christensen et al.
2009; Teschendorff et al. 2010; Bocklandt et al. 2011). a-DMRs have implications for gene
activity. Several large-scale studies of aging in humans examined gene expression, DNA
methylation, or both (Table 2.1) and found that not only do DNA methylation marks correlate
with age but are also predictive of gene expression levels (Steegenga et al. 2014). As we show in
our preliminary data (Table 2.1), human genome-wide studies of blood DNA have shown that
genes involved in the Absorption, Distribution, Metabolism, and Excretion (ADME) of drugs are
differentially methylated with age. However, it has not yet been established if these changes also
occur in the liver and affect expression levels of genes involved in drug metabolism.
Furthermore, we do not know if these changes exert any functional effect on rates of drug
clearance in vivo. Therefore, further studies are needed to determine if a-DMRs at ADME genes
affect drug metabolism.
1.5. Discussion and Conclusions
Epigenomic medicine is already here, with numerous epigenetic disease associations
reported, six epidrugs and a handful of epigenetic biomarker tests available the US, plus a small
number of other products available worldwide. The largest number of findings and applications
to date is in the field of oncology. However, the field of epigenetics is only a few decades old
and epigenomic medicine is a very recent arrival, so we are still in early days. The perceived
benefits that epigenomics will bring to healthcare are emphatically illustrated by the large
number of epidrugs currently in development and the large sums of research dollars spent on
large-scale discovery efforts such as RoadMap Epigenomics. To drive the field forward,
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epigenomic medicine needs to expand beyond cancer. Also, while significant efforts are being
devoted to bringing new epidrugs to market, more efforts must be devoted to developing new
epigenetic biomarkers, of which there are few.
Several factors are currently driving innovation in epigenomic medicine. First is the general
level of interest in the field, which is high. Second is the ongoing characterization of reference
epigenomes to enrich and accelerate research efforts. Third is the availability of powerful
methods such as next-generation sequencing (NGS) to characterize epigenomes. Discussion of
technical methods is largely outside the scope of this chapter and reviews have been published
elsewhere (Laird 2010; Krueger et al. 2012). However, with NGS approaches already in use to
characterize genome-wide DNA methylation and protein-DNA binding patterns, we would argue
that technology is not a bottleneck for the advancement of epigenomic medicine.
Considering epigenomic biomarker research, among the most significant difficulties are data
complexity and the clean interpretation of findings (Ledford 2015). Unlike studies of genotype,
epigenomics has a direction of causality problem. While epigenetic biomarkers may be
predictive of disease state or drug response, epigenetic changes are also inducible by
pharmacological treatments (Feinberg 2007; Wang et al. 2007). As a result, there is the risk that
epigenetic differences between cases and controls in an epigenome-wide association study could
be the result of drug treatment in cases, rather than causal variation. Furthermore, evidence from
genome-wide studies suggests that not all epigenetic changes are functional or cause identifiable
changes to gene expression (Stricker et al. 2017). Targeting specific populations, such as drugnaïve patients, may go some way to solving issues related to the direction of causality, but it is
certain that experimental model systems will be needed to adequately disentangle causality and
establish functionality of epigenetic changes.
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Another complexity is that epigenetic modifications are cell specific. While this is in
many ways an advantage and can give precise insight into the workings of the cell of origin, it
also leads to some challenges in sample collection, particularly with respect to clinical studies.
Blood DNA is the most readily-accessible source from humans, but the extent to which blood
DNA methylation is reflective of methylation changes in other tissues is debated and it seems
there may not be a hard and fast rule with respect to which changes are reflected in blood as
compared to which are not. Aging epigenetic signatures, also known as the “epigenetic clock”,
appear to transcend tissue barriers (Horvath 2013), but the extent to which a blood DNA
methylation mark is informative about a disease of, for example, the lung or heart remains an
open question. Circulating cfDNA is an exception, since it is sourced from the diseased tissue of
interest and is merely liberated into the bloodstream.
While these considerations apply to the discovery of novel epigenetic biomarkers, a
separate set of considerations apply to novel epigenetic drugs. Paramount among priorities for
future epidrug development is improving target specificity. This can be viewed in two ways.
First, as mentioned above, current drugs lack genomic locus specificity and affect DNA
methylation or histone modifications somewhat indiscriminately. To truly enable precision
correction of aberrant changes, some sort of nucleic acid targeting adjunct is likely to be
required. While antisense RNA (MG98) has already been used to modulate DNMT activity with
some success (Reid et al. 2002), it is difficult to speculate how this could be used to target
epigenetic modifications at specific target loci. On the other hand, it may be possible to
capitalize on the locus targeting abilities of CRISPR/Cas9 systems to deliver epigenetic
modifying agents to specific loci. Indeed, epigenome editing has already been demonstrated
using this broad approach (Thakore et al. 2016). A second consideration involves the specificity
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of epidrugs to specific members of families of chromatin modifying enzymes. For example, there
are numerous human DNMTs and HDAC enzymes with somewhat different functions and
substrate specificities but currently available DNMTi and HDACi are non-selective and inhibit
many isozymes. However, some drugs currently in clinical trials appear to be more selective, e.g.
mocetinostat that inhibits only HDAC 1 and 4 (see Table 1.3). Thus, the problem of specificity
does not appear to be insurmountable. To conclude, we mention two areas, one technological and
one clinical, that we consider to be of significant interest going forward.
In the clinical arena, aging is an area where epigenomic medicine may make an impact.
Older adults are at increased risk for adverse drug events and this may be partly because aging is
associated with changes in physiology that can affect drug pharmacokinetics and
pharmacodynamics (Fillit et al. 2017). The clinical challenge is to identify those patients who are
more likely to experience an adverse drug event or altered drug response among the older adult
population when weighing the risk versus the benefit of a drug therapy. Chronologic age alone is
insufficient as an indicator that dosage adjustment or avoidance of a particular therapeutic agent
is warranted. Pharmacogenetic information alone is also insufficient, as altered drug response
and risk of adverse drug events changes across the lifespan while genotype remains constant
(Brunet and Berger 2014; Pal and Tyler 2016). Epigenetic alterations may be a better indicator
than chronological age for personalizing drug therapy for the older population. For example, it
has been proposed that epigenetic regulation of cytochrome P450 (CYP) enzymes responsible for
drug metabolism through DNA methylation may result in altered drug exposure in geriatric
patients (Seripa et al. 2015). More research is needed to elucidate the relationships between
epigenetics and drug exposure and response during senescence but is a promising alternative to
chronologic age for adjusting pharmacotherapy in older adults.
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2.1. Abstract
Aging is associated with reduced liver function that may increase the risk for adverse
drug reactions in older adults. We hypothesized that age-related changes to epigenetic regulation
of genes involved in drug metabolism may contribute to this effect. We reviewed published
epigenome-wide studies of human blood and identified the cytochrome P450 2E1 (CYP2E1)
gene as a top locus exhibiting epigenetic changes with age. To investigate potential functional
changes with age in the liver, the primary organ of drug metabolism, we obtained liver tissue
from mice aged 4-32 months from the National Institute on Aging. We assayed global DNA
methylation (5mC), hydroxymethylation (5hmC) and locus-specific 5mC and histone acetylation
changes around mouse Cyp2e1. The mouse livers exhibit significant global decreases in 5mC
and 5hmC with age. Furthermore, 5mC significantly increased with age at two regulatory regions
of Cyp2e1 in tandem with decreases in its gene and protein expression. H3K9ac levels also
changed with age at both regulatory regions of Cyp2e1 investigated, while H3K27ac did not. To
test if these epigenetic changes are associated with varying rates of drug metabolism, we assayed
clearance of the CYP2E1-specific probe drug chlorzoxazone in microsome extracts from the
same livers. CYP2E1 intrinsic clearance is associated with DNA methylation and H3K9ac levels
at the Cyp2e1 locus but not with chronological age. This suggests that age-related epigenetic
changes may influence rates of hepatic drug metabolism. In the future, epigenetic biomarkers
could prove useful to guide dosing regimens in older adults.
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2.2.

Introduction

Adverse drug reactions (ADRs) are estimated to be between the fourth and sixth leading
cause of death in the United States (Lazarou et al. 1998). The impact and management of ADRs
are complex and has been estimated to cost up to $30.1 billion annually (Sultana et al. 2013).
Previous research suggests that rates of ADRs increase as people age, have more chronic health
conditions, and take more medications (McLean and Le Couteur 2004; ElDesoky 2007; Budnitz
et al. 2011). Human life expectancy has more than doubled in the last two centuries, and while
mortality has been delayed, aging is still accompanied by a significantly elevated risks for many
diseases (Issa 2002; Duron and Hanon 2008; Barzilai et al. 2012). Comorbid chronic conditions
in individuals older than 65 years cause high degree of polypharmacy in this population.
According to a 2006 survey, 40% of persons 65 years of age or older were taking five to nine
medications, while almost one fifth (18%) were taking 10 or more (Slone Epidemiology Center
2006). Ultimately, older adults are almost seven times more likely than younger persons to have
ADRs that require hospitalization (Budnitz et al. 2006). While ADRs are a serious problem in
the aging population, up to 80% of ADRs in older patients are dose related and therefore, are
potentially avoidable (Routledge et al. 2004). This implies that effective methods for predicting
the correct dose for the individual patient could make a significant impact in geriatric healthcare.
Age-associated changes to hepatic metabolism of drugs increase risk for ADRs in older
adults (McLachlan et al. 2009; McLachlan and Pont 2012) but the determinants of these changes
are not fully understood. One possible mechanism that may influence rates of drug metabolism
in older adults is epigenetics (Seripa et al. 2015; Fisel et al. 2016; Kronfol et al. 2017). Aging is
associated with substantial changes to the epigenome (Benayoun et al. 2015; Pal and Tyler 2016;
Horvath and Raj 2018) and genes encoding drug metabolizing enzymes in human liver are under
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epigenetic control (Bonder et al. 2014, Park et al. 2015). Furthermore, treatment with epigenetic
drugs affects the metabolic capacity of cultured cells (Ruoß et al. 2019). These considerations led
us to hypothesize that age-associated epigenetic changes at genes encoding drug metabolizing
enzymes could affect rates of drug metabolism. Epigenome-wide association studies (EWAS) in
human blood have found significant changes to DNA methylation at several genes encoding
phase I (oxidative) drug metabolism enzymes with age (Heyn et al. 2012; Hannum et al. 2013;
Horvath 2013; Steegenga et al. 2014; Reynolds et al. 2014; Marttila et al. 2015; Peters et al.
2015). However, the extent to which these age-related changes are present and affect enzymatic
activity in the liver, the primary site of drug metabolism, is unclear. Therefore, the goal of this
study is to identify age-related epigenetic changes at phase I genes encoding drug metabolizing
enzymes in the liver and test if these epigenetic changes are associated with rates of drug
metabolism. Due to the experimental control afforded and availability of the relevant tissue, we
chose to conduct the experiments in mice.
To date, the number of published studies on epigenetics and drug metabolism in aging is
limited. As a starting point to identify potential genes of interest, we reviewed published EWAS
and genome-wide gene expression studies in human blood and chose the phase I drug
metabolism genes showing the best empirical evidence of change with age. The rationale for
using human blood studies to guide gene selection is because 1) the largest number of aging
EWAS have been conducted in this tissue, 2) epigenetic aging effects are significantly correlated
across tissues and species (Horvath 2013) and 3) consistent patterns of gene expression changes
with age have been observed across several species (McCarroll et al. 2004). We identified two
phase I drug metabolism genes, CYP2E1 and CYP1B1, showing strong evidence for ageassociated epigenetic changes in human blood. We mapped the associated regions in the human
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genome to their homologous mouse regions and tested for epigenetic changes in mouse liver.
Only Cyp2e1 showed differential methylation with age. Based on these results, we focused on
Cyp2e1 and conducted a detailed analysis of regulation at this locus including assays for DNA
methylation and histone post-translational modifications (PTMs) with reported associations with
age (McClay et al. 2014; Dozmorov 2015). Finally, we investigated if these effects were
associated with CYP2E1 metabolic function by isolating liver microsomes and applying
Michaelis–Menten kinetics to determine the intrinsic clearance (CLint) of the probe drug
chlorzoxazone (CZ), which is predominantly metabolized by CYP2E1 (Lucas et al. 1999).

38

2.3.

Methods

2.3.1. Mice: Liver tissue samples from 20 male CB6F1 mice (5 subjects in each of four
age groups 4, 18, 24, and 32 months) were obtained from the National Institute on Aging (NIA)
tissue bank.
2.3.2. DNA and RNA extraction: Genomic DNA was extracted using the AllPrep
DNA/RNA kit (80204, Qiagen, Hilden, Germany) according to manufacturer’s protocol. DNA
and RNA purity and quantity were measured using a Nanodrop spectrometer (ThermoFisher,
Waltham, MA).
2.3.3. Global 5-MethylCytosine (5mC) and 5-HydroxymethylCytosine (5hmC): Global
5mC and 5hmC levels were measured using ELISA colorimetric assays by MethylFlash kits
(1030-96, 1032-96, Epigentek, Farmingdale, NY). 5mC- or 5hmC-specific antibodies, provided
in the kit, were incubated with 100ng genomic DNA. Optical density at 450 nm was measured on
a Synergy HT plate reader (BioTek Instruments, Winooski, VT). Known standards provided in
the kit consisting of 0.1, 0.2, 0.5, 1, 2, and 5% for 5mC and 0.02, 0.04, 0.1, 0.2, 0.4, and 1% for
5hmC were also assayed. The optical density of liver samples was used to determine the
percentage of 5mC and 5hmC of each sample by interpolation on respective standard curves.
Each unknown and standard was run in duplicate.
2.3.4. Selection of genomic regions of interest: Aging EWAS findings for human blood
were obtained from published studies (see Dozmorov 2015) and genes encoding drug
metabolizing enzymes were obtained from the ADME (absorption, distribution, metabolism, and
excretion) gene list from the pharmaADME consortium (pharmaADME.org), see Table 2.1.
Significant findings by ADME gene were summed across studies and the top two phase I drug
metabolism genes showing the most significant findings were selected for study.
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Reference

CYP2E1
CYP1B1
CYP2J2
CYP1A1
ADHFE1
PDE3B
DHRS9
CYP2D6
CYP3A4

Longevity Map (Human
Ageing Genomic Resources)
Exp

Peters et
al. 2015
Exp

X
X

X
X
X

Heyn et
Hannum et
al. 2012
al. 2013
Meth
Meth
Phase I genes

Horvath
2013
Meth

Reynolds et
al. 2014
Meth

Marttila et
al. 2015
Both

X

Steegenga et
al. 2014
Both
X

X

X
X

X

X
X
X
X

X
X
X

X

Table 2.1. Summary of human EWAS findings for phase I drug metabolism genes. Human ADME genes list from pharmaADME
(www.pharmaadme.org) was contrasted on the top findings from EWAS and gene expression studies of normal aging in human blood
DNA. Genes encoding phase I drug metabolizing enzymes that showed significant association in the top findings of these studies is
marked with an “X”. The total number of studies were a specific gene is a top association in the reported results is shown as a total in
the last column of the table. Exp: Expression, Meth: Methylation.

Total
4
4
2
2
2
2
2
1
0
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Genomic location of human age-associated Cytosine-phosphate-Guanine (CpG) positions
were used to extract the homologous regions in mouse using the “convert” function in the
University of California Santa Cruz (UCSC) genome browser (Kent et al. 2002). A complete list
of the genomic coordinates of all investigated regions in mouse can be found in Table 2.2. An
additional regulatory region around human CYP2E1 was identified using the GeneHancer track
(Fishilevich et al. 2017) on the UCSC genome browser (Figure 2.1). Data from the mouse
Encyclopedia of DNA Elements (ENCODE) (Stamatoyannopoulos et al. 2012) and Ludwig
Institute for Cancer Research (LICR) (Barrera et al. 2008) chromatin immunoprecipitation
(ChIP) sequencing runs on young (8 weeks) male mouse liver tissue were used to identify two
regions with high levels of histone 3 lysine 9 acetylation (H3K9ac) and histone 3 lysine 27
acetylation (H3K27ac) PTMs (GSM1000153, GSM1000140).
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Primers (5’→ 3’)
Gene

Forward Primer

Reverse Primer

Product size/coordinates/assembly

High-Resolution Melt

CpG count

Cyp2e1

AATTAGTATTTTAGGTTAAGGGAGATGAGTGG

TCCCTTACCTTAATTAAAAACTTAAAAATATCCTTC

319/chr7:147,949,616-147,949,934/mm9

7

Cyp1b1

TGTTTTGTTGTATTAGGGTTTGGTGGATGG

CCTTTATATCCCCAACATAACCACCAAC

350/chr17:80,113,318-80,113,667/mm9

21

Chromatin Immunoprecipitation Quantitative Polymerase Chain Reaction
Cyp2e1
Region 1

ATGCTGAGCCAGCTGTGA

CCACATGCAAAGACAATCCT

145/ chr7:147,950,223-147,950,367/mm9

Region 2

ATTTGCTGCCTAGCTGCTTC

CAGCACTCTGAGACCCCAGT

119/ chr7:147,942,350-147,942,468/mm9

AGAGAGGGAGGAGGGGAAATG

AACAGGGAGGAGCAGAGAGCAC

200/ chr6:125,115,604-125,115,803/mm9 a

CTCCAGATGCTGAGAGAAAAAC

AGGCATACCAAGCACAGAAA

100/ chr17:95,049,080-95,049,179/mm9

Gapdh
Positive
control
Negative
control

Table 2.2. HRM and ChIP primers and qPCR product sequences. Primers used in the High-Resolution Melt and Chromatin
Immunoprecipitation Quantitative Polymerase Chain Reaction assays with size of PCR product, genomic coordinates, and assembly
with CpG count when appropriate. a blasted from Pace et al., 2018 to obtain coordinates
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Figure 2.1 Illustration showing the transcription start site (TSS) and upstream regulatory regions of the human CYP2E1 and the
homologous mouse Cyp2e1 gene. Upstream regulatory element positions were obtained from GeneHancer (Fishilevich et al. 2017)
and ORegAnno (Lesurf et al. 2016). DNA methylation assays were conducted in the current study at both the TSS and upstream
regulatory region in mouse at positions marked by the arrows. Reference histone 3 lysine 9 acetylation (H3K9ac) and histone 3 lysine
27 acetylation (H3K27ac) in 8-week-old mouse livers are from the ENCODE/LICR track in UCSC Genome Browser. Two loci with
high liver histone acetylation levels were chosen for analysis using ChIP-qPCR in the current study, at positions marked by the
arrows. For exact assay coordinates see Table 2.2 and Table 2.3.
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Region
Product size/coordinates/assembly
Forward primer
Reverse primer
Sequencing primer
M13 primer a
CpG count

Cyp2e1 Region 1
275/chr7:147,949,576-147,949,850/mm9

Cyp2e1 Region 2
157/ chr7:147,942,437-147,942,593/mm9

5’GGGGGTAGGTTTTAATTTTTATAGAT3’
5’TTAGTATTTTTATTGGGGTTTTAGAGTG3’
5’CGCCAGGGTTTTCCCAGTCACGAC
5’CGCCAGGGTTTTCCCAGTCACGAC
ATCAACCTTTAAAATAATAACCAACTACA3’
ATAACCTCCAAATCTAAACTTCTATTTAAC3’
5’ATTTTTATAGATTTGTTTTTAGATG3’
5’GTTGGAGTTTAATGGGA3’
5’biotin-CGCCAGGGTTTTCCCAGTCACGAC3’

7

1

Table 2.3. Pyrosequencing primer sequences. Primers used in the Pyrosequencing assays of region 1 and 2 with size of pyrosequenced
PCR product, coordinates, and assembly with CpG count. aM13 primer sequence published in Royo et al. 2007.
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2.3.5. Bisulfite conversion of genomic DNA and High-Resolution Melt (HRM) analysis:
200ng of liver genomic DNA was treated with sodium bisulfite according to the EZ DNA
Methylation kit protocol (D5002, Zymo Research, Irvine, CA). Mouse genomic DNA of 5 and
85% methylation were used as standards (808063, 808064, EpigenDx, Hopkinton, MA). Ratios
of the standard DNA were mixed at 5, 25, 45, 65, and 85% to create a standard curve. A negative
(no template) control was also used per plate. High-Resolution Melt (HRM) assays using
MeltDoctor HRM MasterMix (4409535, Applied Biosystems, Foster City, CA) on a Quantstudio
3 instrument were used to measure 5mC levels at LINE1 elements using the method of Newman
et al. (2012) with minor modifications and at a 319 base pair region on the 5’UTR of mouse
Cyp2e1 (chr7:147,949,616-147,949,934, mouse genome assembly mm9 NCBI37/ build 9, July
2007) encompassing 7 CpGs (Table 2.2). For Cyp2e1, samples were amplified by qPCR as
follows 10min hold at 95ºC followed by 40 cycles of: 15sec at 95ºC, 30sec at 57ºC and 30 sec at
72ºC, followed by a final extension at 72ºC for 7 min and a melt curve stage with temperature
range of 57ºC to 95ºC with fluorescence capture at 0.025 degrees per second increment. Each
reaction included 20ng bisulfite-converted DNA and final concentration of 1X MeltDoctor HRM
MasterMix (Applied Biosystems), 0.2µM forward and 0.2µM reverse primer (Table 2.2).
HRM LINE1 assay was performed as described previously (Newman et al. 2012) with
slight adjustments. MeltDoctor HRM MasterMix (Applied Biosystems, Foster City, CA) on a
Quantstudio 3 instrument was used to measure 5mC levels at the 193 base pair LINE1 region
reported in Newman et al encompassing 11 CpGs. Samples were amplified by qPCR as follows
10min hold at 95ºC followed by 45 cycles of: 15sec at 95ºC, 60sec at 60ºC, followed by a melt
curve stage with temperature range of 60ºC to 95ºC. Each reaction included 20ng bisulfiteconverted DNA and 0.75µM each of unmethylated forward and reverse primer (Newman et al.

45

2012) in 1X MeltDoctor HRM MasterMix. Standards of 0, 25, 50, 75, 100% methylation
(EpigenDx, Hopkinton, MA) were run in duplicate while the liver samples were run in triplicate.
The NTS values (Newman et al. 2012) of the liver samples were interpolated on the standard
curve to yield their 5mC percentage.
2.3.6. Gene expression analysis by reverse transcription – quantitative PCR (RT-qPCR):
For each sample, 1µg of total liver mRNA was reverse transcribed to cDNA by iScript kit
according to manufacturer’s protocol (1708891, Bio-Rad, Hercules, CA). Aliquots of cDNA
were amplified in triplicate using final concentration of 1X TaqMan master mix (4369016,
Applied Biosystems) and 1X TaqMan Cyp2e1 Mouse Gene Expression Assay
(Mm00491127_m1, ThermoFisher) (Martinez et al. 2010; Koh et al. 2011). qPCR conditions
were as follows 40 cycles of 15 sec at 95ºC and 60 sec at 60ºC. Mouse Gapdh endogenous
control was also assayed in triplicate (Mm99999915_g1, ThermoFisher) (Scarzello et al. 2016;
Wilhelm et al. 2016; Jia et al. 2018). A 1:2 serial dilution of control cDNA was used to generate
a 5-point standard curve. Quantification cycles (Cq) were determined using the Relative
Quantification application on the ThermoFisher Cloud. Normalized quantification cycles (ΔCq)
were obtained by subtracting the mean Gapdh Cq from the mean Cyp2e1 Cq. ΔΔCq was
calculated for each age group by subtracting the ΔCq of the 4 months (youngest age group as
reference) from each of the other age group’s ΔCq to calculate fold differences.
2.3.7. Western Blots: Cell protein lysates were created from homogenization of 20mg
liver tissues in 200µL Pierce RIPA buffer (89900, Thermo Fisher, Waltham, MA) with final
concentration of 1% v/v (2 µL) Halt Protease Inhibitor buffer (78430, Thermo Fisher, Waltham,
MA). The Pierce BCA assay (23227, Thermo Fisher, Waltham, MA) was used to measure
protein concentrations using manufacturer’s standard protocol. Absorbance at 562nm was
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measured on a Synergy HT plate reader and the unknown protein concentration was determined
by interpolating absorbance of unknown samples on an 8-point standard curve created from
diluted albumin standards.
10µg of total protein in 30µL β-Mercaptoethanol (βME)-Laemmli buffer (1610710,
1610747, Bio-Rad) were separated on 10% Mini-PROTEAN precast SDS-PAGE gels (4568033,
Bio-Rad) at constant 200V for 35min and transferred onto PVDF membrane using a TransBlot
Turbo (1704150, Bio-Rad) at 1.3A for 5 min. Membranes were blocked for 30 min in 5% milk in
1X TBST (Tris Buffered Saline, Tween20). Blots were probed using anti-CYP2E1 primary
antibody (1:2500, ab28146, Abcam) in 10mL 5% Milk in 1X TBST at 4ºC overnight and washed
three times with 1X TBST the next day. The blots were incubated with HRP-coupled rabbit IgG
secondary antibody (1:10000, Cell Signaling, Danvers, MA) and 0.5µL Precision Protein
StrepTactin-HRP conjugate (Bio-Rad) for 1hour at RT in 10mL 5% Milk in 1X TBST.
Membranes were washed five times with 1X TBST. Blots were treated with 2mL Clarity
Western ECL (1705060, Bio-Rad) at 1:1 clarity western luminol enhancer: peroxide solution
ratio to start chemiluminescence and imaged 2min afterwards on the ChemiDoc Touch (BioRad). Blots were washed with 1X TBST and stripped for 30min using Restore stripping buffer
(21059, Thermo Fisher). After stripping, the membrane was incubated with GAPDH primary
antibody (1:5000, MA5-15738, Thermo Fisher) and then mouse IgG secondary antibody
(1:20000, 7076S, Cell Signaling, Danvers, MA). The bands were visualized at 49 and 37 kDa for
CYP2E1 and GAPDH respectively using Image Lab software v 6.0 (Bio-Rad, Hercules, CA).
For each sample, CYP2E1 band intensity were normalized to GAPDH.
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2.3.8. Chromatin Immunoprecipitation Quantitative Polymerase Chain Reaction (ChIPqPCR): 80 mg of mouse liver was minced into 1 mm3 fragments with -20 C precooled scalpel
and transferred to 2mL Eppendorf tube. TruChIP tissue shearing kit (520237, Covaris, Woburn,
MA) was used to prepare sheared chromatin. Centrifugations were at 200g for 5 min at 4ºC
unless otherwise noted. The minced tissue was washed with 1 mL 1X cold PBS and centrifuged
at 200g for 5min at 4ºC. The supernatant was discarded and 1mL of fixing buffer A was used to
resuspend the pellet. 100µL of freshly prepared 11.1% methanol-free formaldehyde (1% final
concentration) was added and the fixation was quenched after 2 min with 58µL quenching buffer
E. The suspension was centrifuged, and the supernatant discarded. Pellet was washed twice with
1mL 1X cold PBS and centrifuged. Pellet was transferred to tissueTUBE (TT05M XT) provided
in the kit and flash frozen in liquid nitrogen for 45sec and pulverized into powder by a precooled
pestle. Pulverized tissue was transferred by inverting to a screwed-on milliTUBE-2mL and
stored at -80ºC until nuclei separation and shearing step the next day. Pulverized tissue was
transferred to a 2mL Eppendorf tube using two successive transfers by 500µL lysis buffer B. The
2mL tube was incubated on a rotor at 4ºC for 20min to complete lysis. Nuclei were pelleted by
centrifugation at 1700g for 5min at 4ºC. Supernatant was discarded and pellet was resuspended
in 1mL wash buffer C and incubated on a rocker for 10min at 4ºC. Nuclei were pelleted again at
1700g for 5min at 4ºC and supernatant discarded. Pellet was resuspended with 1mL wash buffer
C and centrifuged at 1700g for 5min at 4ºC. Pellet was resuspended with 1mL shearing buffer
D2 and sheared on M220 (Covaris, Woburn, MA) for 8min at 75 PIP, 10% duty factor, 200CPB,
7C set point temperature (4/10 Min/Max), and no degassing. Time course trials were conducted
to determine optimal shearing (2-20 min) and fixation times (2 and 5 min) of 8 and 2 min
respectively which yielded the highest percentage (>75%) of fragment sizes between 150 and
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700 bp and the lowest percentages (<25%) of fragment sizes less than 150 and higher than 701
bp combined. Shearing and fixation time course trials were analyzed on the Agilent 2100
Bioanalyzer using the Agilent DNA 12000 chip on Agilent 2100 expert software. 25µL of
sheared chromatin was incubated with 1µL 10mg/ml RNAse (EN0531, Thermo Fisher,
Waltham, MA) at 37ºC for 30min, then it was treated with 4µL 10mg/ml Proteinase K (17916,
Thermo Fisher, Waltham, MA) at 65ºC overnight (16 hours). DNA was purified using QIAquick
PCR purification Kit (Qiagen, Hilden, Germany). The concentration of eluted DNA was
measured on Qubit 4.0 fluorometer and used to calculate the volume required to have 2µg
sheared chromatin as starting material for the Chromatin immunoprecipitation (ChIP) step (1:1
ratio of DNA to chromatin was used to calculate chromatin concentration). The sheared
chromatin was diluted 1:2 with 3X Covaris IP dilution buffer in order to decrease final SDS
concentration to 0.083% and prevent SDS interference with epitope and antibody binding.
Each ChIP had 2µg of sheared chromatin. 2% of the volumes of sheared chromatin per IP
was set aside at 4ºC as input control and was not processed through ChIP step. ChIP was carried
out by incubating 5 µL of H3K9ac (39137, Active Motif, Carlsbad, CA), or 5µL of H3K27ac
(39133, Active Motif, Carlsbad, CA), or 5µL of Rabbit IgG (ab171870, Abcam) with 2µg
sheared chromatin from each sample overnight (16 hours) at 4ºC. Hence, three worth of ChIP
volumes were used from each sample. The formed complex was incubated with 50 µL
Dynabeads Protein G (10003D, Thermo Fisher, Waltham, MA) for 4 hours at 4ºC. The bead
linked complex was inserted on the DynaMag (Thermo Fisher, Waltham, MA) magnet rack for 2
min and the supernatant discarded. The bead coupled complex was removed from the magnet
and washed 3 times with 500 µL with cold 0.05X Tween 20 in PBS PH7.4 (10010023, Thermo
Fisher, Waltham, MA) for 3 min each at room temperature on HulaMixer (Thermo Fisher,
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Waltham, MA). Finally, 50 µL of IP elution buffer (Aq. 1% SDS, 0.1 M NaHCO3, pH 9.0) was
added to the bead coupled complex and incubated on a heat block for 1hour at 65ºC with 15sec
vortexing every 15 min. The samples were then inserted back on the DynaMag for 2 min and 50
µL of the supernatant was transferred to a 96 well PCR plate. The input control was diluted 1:2
with 3X Covaris IP dilution buffer to mimic the dilution done to the samples and preserve its
percentage (2%). The ChIP’ed samples and their input controls were incubated each with 2 µL
RNAse for 30 min at 37C and then 8 µL of Proteinase K was added and incubated overnight (16
hours) at 65ºC. The next day, DNA was purified using QIAquick PCR purification kit (Qiagen,
Hilden, Germany) to final elution volume of 50 µL. 2 µL of each DNA elution (H3K9ac,
H3K27ac, IgG, and input control) per sample was used per qPCR reaction.
Each ChIP’ed DNA was amplified in triplicate using PowerUp SYBR Green (A25742,
Applied Biosystems), with 0.2 µM of forward and reverse primers (Table 2.2) as follows: 2min
at 50ºC, 2min at 95ºC followed by 40 cycles of: 15sec at 95ºC, 30sec at 59ºC and 1min at 72ºC,
followed by melt curve stage. This stage is as follows: 15sec hold at 95ºC followed by 1min hold
at 59ºC and then the continuous fluorescence acquisition starts while increasing the temp by
0.15ºC/s to end at 95ºC followed by a 15sec hold at 95ºC. Primer specificity and efficiency were
tested on 2% agarose gel and a 5-point 1:2 serial dilution standard curve respectively. No
secondary amplification or primer dimers were detected indicating primer specificity. A singular
melt peak was shown by the qPCR melt curves indicating formation of a single product. Primer
efficiency outside of accepted ranges [90-110] were discarded until reaction conditions were
optimized. Cq values for each plate were downloaded and the mean threshold cycle (Cq)
obtained for each sample and normalized to the dilution factor (2%=1/50) corrected Cq value
(Log2 (50) =5.6438) of the input control to obtain ΔCq. The percentage of input was calculated
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by multiplying 100 with 2 raised to the exponent of Delta Cq. For each sample, three “percentage
of input” values were obtained and are H3K9ac, H3K7ac, and IgG.
2.3.9. Pyrosequencing: Quantitative methylation measures of individual CpGs were
assessed with Pyrosequencing of bisulfite converted DNA (Tost et al. 2003). Primers targeting
the loci of interest were designed with PyroMark Assay Design version 2.0.1.15 (Qiagen) (see
Table 2.3 for details). The first pyrosequencing assay amplified a 257 base pair product at
Cyp2e1 5’UTR (chr7:147,949,576-147,949,850/mm9) that encompasses 7 CpGs (Position 2-8)
chr7: 147,949,679 - 147,949,684 - 147,949,743 - 147,949,754 - 147,949,770 - 147,949-791 147,949,806, mm9. The second assay amplified a 157 base pair product at Cyp2e1 promoter
(chr7:147,942,437-147,942,593, mm9) that encompass 1 CpG (Position 1) chr7: 147,942,492,
mm9. Amplification was performed using the PyroMark PCR Kit (978703, Qiagen) and the
vendor specified program for bisulfite converted DNA. The final concentrations in the PCR
reaction mixture as follows: 1x PyroMark PCR Master Mix, 1x CoralLoad Concentrate, 1.5mM
MgCl2, 1x Q-Solution, 10 ng of bisulfite modified genomic DNA, and 0.2µM of Forward,
0.2µM Reverse, and 0.2µM biotinylated M13 (Royo et al. 2007) primers (Table 2.3). 2µL of the
PCR product was separated by 2% agarose gel electrophoresis to confirm correct product size
and absence of primer dimers and secondary amplification. The 2% agarose gel was made with
the following ratio to obtain 0.75mm thickness in the Owl EasyCast B2 Mini Gel Electrophoresis
System cast (Thermo Fisher Scientific, Waltham, MA): 2.52 g of agarose powder (BP2410-100,
Fisher Scientific, Hampton, NH) and 1.89 µL ethidium bromide (BP1302-10, Fisher Scientific,
Hampton, NH) in 126 mL 0.5X Tris-Borate-EDTA (TBE) buffer (95:5, H2O:10XTBE (BP13334, Fisher Scientific, Hampton, NH)) mixed until complete gelling of agarose. The gel was poured
onto cast and let to solidify for 30 min at RT. The cast was filled with 400 µL 0.5X TBE buffer.
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Each gel had 2µL of 100 bp DNA ladder in the first and last well of the gel. The gel was run on
constant voltage of 100V for 1 hour. The gel was imaged on ChemiDoc Touch (Bio-Rad,
Hercules, CA) using default settings of auto optimal exposure for ethidium bromide stained gels.
Next, 5µL of PCR amplicon were bound with 2µL to Streptavidin Sepharose beads (45000-279, Fisher, Hampton, NH) by shaking for 5 min in 40 µL Binding buffer (979006, Qiagen,
Hilden, Germany) and 33µL of molecular biology grade water. The complex was transferred to a
96-well HS plate (979101, Qiagen, Hilden, Germany) containing 12µL per well of final
concentration of 0.3µM of sequencing primer in Annealing buffer (979009, Qiagen, Hilden,
Germany) on the PyroMark Q96 vacuum preparation station. The HS plate was inserted on the
PyroMark Q96 MD and the PyroMark Gold Q96 reagents (972804, Qiagen, Hilden, Germany)
were used for each assay to sequence the PCR product. Each pyrosequencing assay was run
duplicate for each sample. A standard consisting of 0, 5, 10, 25, 50, 75, and 100% methylated
mouse genomic DNA was included on each plate (808060M, EpigenDx, Hopkinton, MA). Both
the standard and the liver test samples were pyrosequenced in duplicates.
2.3.10. CYP2E1 intrinsic clearance: Mouse Liver Microsomes (MLM) were prepared as
described previously (Knights et al. 2016). 500 mg of liver tissue was homogenized using the
Fisher 150 homogenizer (15340167, Fisher Scientific) on high speed in cold 10 mL microsome
preparation buffer (10 mM potassium phosphate, pH 7.4, 1.15% (w/v) potassium chloride) 5
times for 30 sec each with 30 sec breaks in between on ice and centrifuged at 700g for 10 min
and 10,000g for 10min at 4ºC on the Optima l-90K ultracentrifuge using the SW41 rotor. The
supernatant was ultracentrifuged at 100,000g for 75min at 4ºC and the microsome pellet
transferred to a precooled 5mL Potter-Elvehjem grinder, ground for 1 min at low speed with 10
strokes, transferred back into microsome preparation buffer, and the ultracentrifugation and
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grinding steps repeated. The suspension containing the microsomes was stored at -80ºC. 10µL of
the microsome suspension was used to measure microsomal protein concertation by the
microplate procedure of the BCA assay (23227, Thermo Fisher).
Standards for CZ and 6-OH-CZ (18869, 10009029, Cayman Chemical, Ann Arbor, MI)
were purchased. Chromatographic separation was achieved using an Agilent 1100 series HPLC
(Agilent Technologies, Santa Clara, CA) system equipped with PerkinElmer series 200 degasser
and auto injector (PerkinElmer, Waltham, MA) and C18 BDS hypersil 50 mm x 4.6 with 5µm
particle size (28105-054630, ThermoFisher) column. Diode array detector was used to monitor
the depletion of CZ and the formation of 6-OH-CZ at the wavelengths 280 and 299 nm for CZ
and 6-OH-CZ respectively. Isocratic gradient elution was used with the initial mobile phase
being 85% aqueous (2% acetic acid (BDH20108.292, VWR, Radnor, PA) and 1% triethylamine
(A12646 Alfa Aesar, Tewksbury, MA), v/v) and 15% methanol (A452-4, Fisher Scientific)
(Table 2.4).
Chromatographic conditions
Column
Column temperature
Flow rate
Wavelength
Injection volume
Run time

BDS Hypersil C18 (50 x 4.6 mm, 5µm)
35 ºC
1.0 mL/min
CZ at 280 nm, 6-OH-CZ at 299 nm
80 µL
6.5 min

Time (minute)
0
1.5
1.6
5
5.1

A (%)
85
85
75
75
85

B (%)
15
15
25
25
15

Table 2.4. HPLC parameters. Chromatography parameters of the isocratic gradient co-elution
and detection method of Chlorzoxazone and 6-hydroxychlorzoxazone. A is the aqueous mobile
phase (2% acetic acid and 1% trimethylamine v/v). B is organic mobile phase (HPLC grade
methanol).
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Total run time was 6.5 min with retention times of 1.86 and 5.17 min for 6-OH-CZ and
CZ respectively. Linear standard curves with R2 ≥ 0.999 were obtained from 0.47-240 µM for 6OH-CZ and 2.34-1200 µM for CZ (Figure 2.2 and 2.3).

Figure 2.2 Chlorzoxazone standard curve. High performance liquid chromatography coupled
with Ultraviolet detection method linearity for parent probe drug Chlorzoxazone. Linear range
established at 2.34-1200 µM. Scatter plot with linear regression line of peak area intensity
(mAU.s) against chlorzoxazone concentration (µM).

Figure 2.3 6-hydroxychlorzoxazone standard curve. High performance liquid chromatography
coupled with Ultraviolet detection method linearity for metabolite 6-hydrozychlorzoxazone.
Linear range established at 0.47-240 µM. Scatter plot with linear regression line of peak area
intensity (mAU.s) against 6-hydroxychlorzoxazone concentration (µM).
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Hydroxylation of chlorzoxazone (CZ) to 6-hydroxychlorzoxazone (6-OH-CZ) was
measured to determine the catalytic activity of CYP2E1. Linearity of metabolite formation with
time and MLM protein concentration established (Figure 2.4 and 2.5). The final concentrations
in the metabolic reactions were 50 mM potassium phosphate buffer pH 7.4, 10 mM MgCl2, 1
mg/ml MLM protein, 1 mM EDTA (E4884, Sigma, St. Louis, MO), 1mM NADPH (AK1395,
AkronBiotech, Boca Raton, FL), 0.5% DMSO (16785, Acros Organics), with incubation time of
25 min at 37 ºC. The final concentration of DMSO in each reaction was maintained at 0.5%.
Each MLM sample was run in 8 MLM reactions that vary by the final concentration (10, 20, 40,
80, 160, 320, 640, 1000 µM) of the parent probe drug (CZ) to determine Michaelis-Menten
kinetic constants. The reaction was stopped with equal volume (150µL) of HPLC grade
methanol (A452-4, Fisher Scientific, Hampton, NH) and centrifuged for 10 min at 20,000g at
room temperature. The supernatant was transferred to 96-well plate and 80 µL was injected into
the High-Performance Liquid Chromatography (HPLC) system.
Reaction rates (pmol/min/mg protein) of 6-OH-CZ formation were plotted against CZ
concentration (µM), and Km and Vmax values were estimated by GraphPad Prism using equation
1 (Eq1), were Y is the reaction rate (pmol/min/mg protein), X is CZ concentration (µM), Vmax is
the maximal reaction rate of 6-OH-CZ formation (pmol/min/mg protein), and Km is CZ
concentration at half maximal rate (µM). Eq1. Y = Vmax ∗ X ÷ (Km + X)
Intrinsic clearance (CLint) is the enzyme-mediated activity toward a drug that would
occur at concentration below Km without physiological limitations such as hepatic blood flow
(Houston 1994). CLint by CYP2E1 for the hydroxylation reaction was calculated according to
equation 2 (Eq2). Eq2. CLint = Vmax ÷ Km
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Figure 2.4 Metabolite formation against time plot. Line plot of 6-hydroxychlorzoxazone (6OHCZ) concentration (µM) against tested total microsome reaction time (min). n=3 for each time
point.

Figure 2.5 Metabolite formation against microsome protein plot. Line plot of 6hydroxychlorzoxazone (6OH-CZ) concentration (µM) against tested final Mouse Liver
Microsome (MLM) total protein concentration (mg/mL). n=3 for each concentration.
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2.3.11. Statistics: Linear regression and Pearson correlation tests were conducted in R
version 3.6.1 (www.r-project.org) with α=0.05. Beta values (β) and Pearson correlation
coefficients (r), are reported. β indicates the degree of change in the outcome variable for every
unit change in the predictor variable, while r indicates the degree of association found in the
correlation test. Replicates beyond 2 standard deviations from the mean of any of the assays
were discarded.
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2.4.

Results

2.4.1. Global epigenetic effects in aged mouse liver
DNA and RNA extractions from the mouse liver samples were successful with an
average 260/280 value of 1.94 [1.8-2.1] for DNA and 2.05 [1.94-2.1] for RNA. Prior to locusspecific analysis, we first assayed age-associated changes to the global abundance of epigenetic
marks in mouse liver. Using ELISA assays, we observed a significant decrease in global
abundance of 5mC (β=-0.011, SE=0.004, p=0.024) and 5hmC (β=-0.001, SE=0.0004, p=0.002)
(Figure 2.6 a, b). This translates to approximately 50% reduction in the 32months age group
compared to the 4 months group for both modifications (0.6% v 0.32% for 5mC and 0.1% v
0.06% for 5hmC). We also measured 5mC at LINE1 elements using High-Resolution Melt
(HRM) analysis of bisulfite converted DNA (Figure 2.7 and 2.8). We observed a significant
decrease in abundance of 5mC at LINE1 elements with increasing age in our sample (β= -2.062,
p= 1x10-8), with an average reduction of 2% methylation per month of age. These results
demonstrated that, in a broad sense, epigenetic changes were occurring with age in this study’s
liver samples.
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Figure 2.6 Box plots with regression line (blue) of Age-Associated changes to global (a) 5MethylCytosine (n=20), (b) 5-HydroxymethylCytosine (n=20). Data represent median (middle
hinge), 25% (lower hinge) and 75% (upper hinge) quantile. Data points beyond upper or lower
1.5 * Inter Quantile Range are represented as individual black dots. (c) Scatter plot of 5MethylCytosine and 5-HydroxymethylCytosine with regression line (blue) (n=20)
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Figure 2.7 LINE 1 methylation percentage per age. Box plots with regression line (blue) of ageassociated changes to LINE 1 methylation percentage (n=20). Data represent median (middle
hinge), 25% (lower hinge) and 75% (upper hinge) quantile. Data points beyond upper or lower
1.5 * Inter Quantile Range are represented as individual black dots.
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Figure 2.8 Representative melt curves per age. Aligned melt curve from the LINE-1 High-

Resolution Melt assay showing representative curves for ages 4, 18, 24, and 32 months. Melt
curves of the 0 and 100 % methylation standard are shown for reference.
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2.4.2. Age-associated changes to Cyp2e1 5’UTR methylation and gene and protein
expression
We reviewed published EWAS and genome-wide gene expression studies of aging in
human blood (Table 2.1) and identified CYP2E1 and CYP1B1 as the phase I drug metabolism
genes showing most evidence for age-associated changes. We mapped the human age-associated
differentially methylated regions from EWAS to their homologous mouse regions and tested for
epigenetic changes at these loci in our aged mouse liver samples. The human CYP2E1 region
mapped to the mouse Cyp2e1 5’UTR (Figure 2.1) and HRM analysis revealed that methylation
at this locus increased significantly with age in mouse liver DNA (β=1.3, SE=0.0038, p=0.002)
(Figure 2.9 a). However, no changes to Cyp1b1 methylation were observed with age (Figure
2.10) so we focused on Cyp2e1.
The observed Cyp2e1 5’UTR methylation increase with age corresponds to a 1.3%
increase in methylation per month of increased age. In tandem, Cyp2e1 gene expression
decreased significantly with age in the same samples (β= -0.03, SE=0.011, p=0.01) (Figure 2.9
b). Using the 4 months group as reference, we observed a 2.15% reduction in expression of
Cyp2e1 per month of increased age. Furthermore, we observed a significant decrease of CYP2E1
protein expression with age, as measured by change in chemiluminescence detected in Western
blot (β=-4.0e+5, SE=0.01, p=0.02) (Figure 2.9 c).
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Figure 2.9 Box plots with regression line (blue) of Age-Associated changes to Cyp2e1 (a) 5’UTR percent methylation (n=19), (b)
gene expression (n=20). (c) Box plot of Age-Associated changes to Cyp2e1 protein expression with representative western blot
(n=20). Data represent median (middle hinge), 25% (lower hinge) and 75% (upper hinge) quantile. Data points beyond upper or lower
1.5 * Inter Quantile Range are represented as individual black dots
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Figure 2.10 Cyp1b1 5mC with age. Boxplot showing no changes to methylation at Cyp1b1 as
age increases from 4 to 32 months.
2.4.3. Base-resolution 5mC analysis of Cyp2e1 5’UTR and upstream regulatory region
Having established that DNA methylation changes were occurring with age at the Cyp2e1
5’UTR, we aimed to obtain a fuller picture of Cyp2e1 epigenetic regulation. Our first priority
was to assay 5mC levels at each of the seven CpGs in the 5’UTR region individually, in contrast
to the aggregate measure obtained via HRM. We also identified an upstream regulatory region in
human CYP2E1 (Figure 2.1) that we used to obtain the homologous region in mouse that
harbored a single CpG. Therefore, we subjected both regions to bisulfite pyrosequencing that
allows highly quantitative methylation measurements at single-base resolution. This revealed
that the single CpG in the upstream regulatory region (position 1, chr7: 147,942,492, mm9) was
significantly hypermethylated with age (p=0.023, Figure 2.11 a & b, position 1).
Pyrosequencing further confirmed the methylation increases at the 5’UTR with age observed via
HRM (Table 2.5), with all individual CpGs showing significant increase in methylation with age
(Figure 2.11 a & b, positions 2 through 8). The CpG at position 5 (chr7: 147,949,754, mm9) was
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the most significantly hypermethylated (p=0.007) with the largest beta value of 0.84% increase
per month of age (Figure 2.11 b).

Figure 2.11 Pyrosequencing data for Cyp2e1. (a) Scatter plot of percent methylation of
Cytosine-phosphate-Guanine (CpG) and all investigated CpG positions with superimposed line
plot for each age group connecting the average methylation percentage at each CpG (n=20 per
CpG, N=80 total). X-axis not drawn to scale. chr 7 = chromosome 7; mm9 = mouse genome
assembly NCBI37/ build 9, July 2007. (b) Scatter plot of CpG methylation and age of individual
CpG positions with regression line and statistics under each location. A simple linear regression
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was performed on all 20 data points for each CpG (n=20) against each age 4, 18, 24, and 32
months (N=80). Position 1-8: chr7: 147,942,492-147,949,679 - 147,949,684 - 147,949,743 147,949,754 - 147,949,770 - 147,949-791 - 147,949,806, mm9.

High Resolution Melt Methylation
Pyrosequencing Methylation

Pearson r

p-value

Pos1

0.5106

0.0013

Pos2

0.4909

0.0003

Pos3

0.5122

0.0015

Pos4

0.4859

0.0002

Pos5

0.5224

0.0007

Pos6

0.5185

0.0011

Pos7

0.3985

8.58E-08

Pos8

0.4035

6.49E-06

Table 2.5. Pyrosequencing and HRM 5mC correlation. Pearson correlation test result rho (r) and
p-value of each CpG methylation values investigated by Pyrosequencing and the HighResolution Melt (HRM) methylation result of the 5’UTR region of Cyp2e1. The pyrosequencing
assays confirmed the HRM data with all CpG positions positively correlated with HRM
methylation. Pos 1-8: Position 1-8 chr7: 147,942,492-147,949,679 - 147,949,684 - 147,949,743 147,949,754 - 147,949,770 - 147,949-791 - 147,949,806, mm9.
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2.4.4. Histone acetylation analysis of Cyp2e1 5’UTR and upstream regulatory region
We viewed publicly available mouse ChIP-Seq data (GSM1000153, GSM1000140) in
UCSC genome browser to identify two regions neighboring and/or overlapping the 5’ UTR and
the upstream regulatory region that showed high histone 3 lysine 9 acetylation (H3K9ac) and
histone 3 lysine 27 acetylation (H3K27ac) occupancy rates in young mouse liver (Figure 2.1).
To assay histone acetylation levels in these regions, we used chromatin immunoprecipitation
coupled to quantitative PCR (ChIP-qPCR). We observed a significant increase in H3K9ac at
Cyp2e1 intron 1, adjacent to the 5’UTR (Region 1, chr7:147,950,223-147,950,367, mm9)
(β=0.133, SE=0.06, p=0.044) and at the upstream regulatory region (Region 2,
chr7:147,942,350-147,942,468, mm9) (β= 0.194, SE=0.08, p=0.041) when regressing ChIPqPCR percentage of input on age (Figure 2.12). This corresponds to a 0.133% and 0.194%
increase in H3K9ac per month of increased age at each site, respectively. However, H3K27ac
levels were stable with age at both regions of Cyp2e1 in this sample.
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Figure 2.12 Chromatin Immunoprecipitation quantitative polymerase chain reaction (ChIP-qPCR) data. Box plots with regression line
(blue) of Age-Associated changes to percentage of input occupancy of Histone 3 Lysine 9 acetylation (H3K9ac) (n=20 per region),
Histone 3 Lysine 27 acetylation (H3K27ac) (n=20 per region) at Cyp2e1 intron 1 (Region1, chr7:147,950,223-147,950,367, mm9) and
promoter (Region 2, chr7:147,942,350-147,942,468, mm9). IgG percentage of input shows a low background noise signal for each of
the sample’s age groups (n=20 per region). Data represent median (middle hinge), 25% (lower hinge) and 75% (upper hinge) quantile.
Data points beyond upper or lower 1.5 * Inter Quantile Range are represented as individual black dots.
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2.4.5. CYP2E1 pharmacokinetics, chronological age, and epigenetics
As shown above, 5mC and H3K9ac levels at Cyp2e1 changed with age in tandem with
reduced gene and protein expression in our sample. To determine if these effects impacted
CYP2E1 metabolic activity, we assayed metabolism of the CYP2E1-specific probe drug
chlorzoxazone (CZ) in microsome extracts from the same livers. The average microsome yield
was 1.07% w/w [0.55-1.69], which was within expected range (Knights et al. 2016). Linearity of
the HPLC assays of R2 ≥0.999 were established for 2.34-1200 µM CZ and 0.46-240 µM 6-OHCZ (Figure 2.2 and 2.3). Linearity of 6-OH-CZ formation with reaction time and MLM final
concentration was established and the final reaction time and MLM concentration was 25 min
and 1 mg/ml respectively (Figure 2.4 and 2.5). Vmax and Km values were estimated and used to
calculate intrinsic clearance (CLint) according to Eq2. Initial analyses established that
chronological age was not significantly associated with CLint of CYP2E1 despite a relatively
large correlation coefficient (r=0.31, p=0.8). Average Michealis-Menten constants and CLint per
age group are reported in Table 2.6. Representative Michaelis-Menten curves of each age group
can be found in Figure 2.13. This result suggests that chronological age is not a robust
independent predictor of CLint, corroborating prior research (Schmucker et al. 1990; Hunt et al.
1990; Mach et al. 2016).
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Age (months)
4
18
24
32

Vmax (pmol/min/mg protein)
Mean (+-SD)
626.05 (297.1)
602.96 (493.9)
915.07 (774.7)
604.8 (434.3)

Km (uM)
Mean (+-SD)
391.44 (196.7)
1009.54 (1662.1)
377.59 (405.2)
732.24 (891.9)

CLint (uL/min/mg protein)
Mean (+-SD)
1.59 (1.51)
0.59 (0.29)
2.42 (1.91)
0.82 (0.48)

Table 2.6 Michaelis-Menten Constants per age group. Table reporting mean (+-SD) of the
pharmacokinetics constants Vmax (pmol/min/mg protein), Km (uM), and CLint (uL/min/mg protein)
per age group (months).
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Figure 2.13 Representative Michaelis-Menten curves of each age group. Representative
Michaelis-Menten curves for (a) 4 months, (b) 18 months, (c) 24 months, and (d) 32 months
ages. X-axis is parent drug chlorzoxazone concentration (µM). Y-axis is reaction rate
(pmol/min/mg protein).

We then tested Cyp2e1 epigenetic measures for association with the pharmacokinetic
variables. All CpGs were associated with CLint (Figure 2.14) and the most significant was with
CpG at position 8 (chr7: 147,949,806, mm9) (r=-0.29, p=0.0008). Furthermore, H3K9ac levels at
the upstream regulatory region, but not intron 1, of Cyp2e1 were positively correlated with CLint
(r=0.49, p=0.005). All p-values are provided in Table 2.7.
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Figure 2.14 Correlation matrix reporting Pearson correlation statistical test result (r). White
blank cells indicate non-significant association (p>0.05). Refer to Table 2.7 for individual pvalues of each Pearson correlation test of a given pair. Color gradient indicates the direction of
effect of the association with dark pink representing the strongest positive association of 1 while
dark gray representing the strongest negative association of -1. Only lower half of the plot is
shown to prevent redundancy in reporting the results. Age: chronological age, Pos 1-8: Position
1-8 chr7: 147,942,492-147,949,679 - 147,949,684 - 147,949,743 - 147,949,754 - 147,949,770 147,949-791 - 147,949,806, mm9. Vmax: maximal rate of hydroxylation reaction of
chlorzoxazone by Cyp2e1, Km: chlorzoxazone concentration at half maximal rate, CL.Int:
intrinsic clearance, K9: Histone 3 Lysine 9 acetylation in Cyp2e1 intron 1 (chr7:147,950,223147,950,367, mm9), R2K9 Histone 3 Lysine 9 acetylation in Cyp2e1 promoter
(chr7:147,942,350-147942468, mm9).
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Age
Age

Pos1

Pos2

Pos3

Pos4

Pos5

Pos6

Pos7

Pos8

K9

R2K9

Vmax

Km

CL.Int

0

Pos1

0.0653

0

Pos2

0.0818

7.70E-14

0

Pos3

0.0716

3.97E-14

3.56E-15

0

Pos4

0.0922

3.79E-12

1.55E-17

9.63E-15

0

Pos5

0.0705

9.53E-14

2.54E-17

8.87E-19

1.48E-16

0

Pos6

0.0820

5.76E-11

9.50E-15

1.47E-12

1.25E-15

1.01E-13

0

Pos7

0.1827

6.65E-08

1.19E-09

1.08E-08

2.97E-10

3.22E-09

2.62E-10

0

Pos8

0.1568

1.93E-09

5.77E-12

2.06E-10

4.16E-13

3.93E-11

1.94E-12

2.02E-13

0

K9

0.0808

0.8220

0.9914

0.8680

0.9338

0.9260

0.8881

0.6116

0.6991

0

R2K9

0.1326

0.3089

0.1978

0.2274

0.1581

0.2115

0.1536

0.0556

0.0843

0.0023

0

Vmax

0.0315

0.3860

0.5458

0.5289

0.6336

0.5521

0.6367

0.9921

0.8266

0.0250

0.0007

0

Km

0.3677

0.1023

0.0681

0.0670

0.0491

0.0668

0.0566

0.0255

0.0298

0.0629

5.46E-05

0.0214

CL.Int

0.8085

0.0030

0.0020

0.0015

0.0012

0.0017

0.0020

0.0008

0.0008

0.5186

0.0050

0.2682 1.79E-05

Table 2.7. Pearson correlation tests p-values for epigenetic and drug metabolism variables. Table reporting Pearson correlation test pvalue for each pair of variables. Age: Chronological age, Pos1-8, Position 1-8: chr7: 147,942,492-147,949,679 - 147,949,684 147,949,743 - 147,949,754 - 147,949,770 - 147,949-791 - 147,949,806, mm9. Vmax: maximal rate of 6-hydroxylation reaction of
chlorzoxazone by CYP2E1, Km: chlorzoxazone concentration at half maximal rate, CL.Int: intrinsic clearance, K9: Histone 3 Lysine
9 acetylation in Cyp2e1 intron 1 (chr7:147,950,223-147,950,367, mm9), R2K9 Histone 3 Lysine 9 acetylation in Cyp2e1 promoter
(chr7:147,942,350-147942468, mm9).

0
0
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2.5.

Discussion

In this study, we demonstrated that 5mC and H3K9ac levels change with age at Cyp2e1
in mouse liver. Furthermore, we showed that these epigenetic changes were significantly
associated with rates of CYP2E1-mediated drug metabolism in microsome extracts from the
same livers, while chronological age was not. This finding suggests that epigenetic marks may be
better predictors of drug metabolism in advanced age than chronological age itself.
Considering our findings in the context of published work, we found that global 5mC
levels diminished with increasing age and this effect has been shown before in studies of
different tissues (Booth and Brunet 2016), including the liver (Wilson et al. 1987). Previous
reports have also shown reduced global 5hmC in mouse liver with age, as we observed here
(Tammen et al. 2014). However, recent genome-wide bisulfite sequencing studies in mouse liver
have shown either a modest excess of hypermethylated sites (Hahn et al. 2017), or no overall
excess in either direction with age (Gravina et al. 2016). One possible reason for this discrepancy
is that “genome-wide” approaches such as next-generation sequencing (NGS) are not truly
representative of the whole genome. For example, NGS approaches typically underrepresent
repetitive elements because reads in these regions may not align unambiguously to the reference
genome and so are discarded. This may diminish the influence of repeats on the cumulative
abundance of methylation in bisulfite sequencing studies. Several classes of repetitive elements
reportedly lose methylation with age (Cardelli 2018). Therefore, underrepresentation of these
elements could lead to underestimation of age-related hypomethylation in genome wide NGS
studies of aging. In our sample, we observed significant hypomethylation of LINE1 elements,
with an average reduction of 2% per month of age. As LINE1 elements are the dominant repeat
class in mouse and human, comprising almost 20% of the genome (Mouse Genome Sequencing
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Consortium et al. 2002), this result could partly explain the discrepancy between global 5mC
studies and genome-wide bisulfite sequencing studies of aging in liver DNA.
Considering our locus-specific results, we found that DNA methylation of the Cyp2e1
5’UTR and upstream regulatory region increased significantly with age, while its gene
expression declined with age. This supports and extends prior observations in human blood
studies. For example, Peters et al. (2015) reported a hypermethylated CpG at human CYP2E1
and decreased gene expression with age. Reduced Cyp2e1 expression was also reported in mouse
liver tissue aged 28 months compared to 4 months, as detected via RNA sequencing (White et al.
2015). To date, prior studies of histone PTM changes in the context of aging are limited and we
are not aware of available published data for the liver. Park et al. (2015) found that histone
deacetylase inhibitors influenced transcription of cytochrome P450s in cultured hepatocytes,
suggesting histone acetylation affects expression, but this study did not examine the effect of
aging nor specific histone acetylation marks. Further work is needed in this area, in particular
genome-wide analysis of H3K9ac with age, given our findings with respect to H3K9ac in this
study.
We observed a significant negative correlation between CLint and Cyp2e1 methylation
and a significant positive correlation between CLint and Cyp2e1 histone acetylation. The effect
sizes are substantial, with a maximum correlation of -0.31 for 5mC and 0.49 for H3K9ac,
suggesting that epigenetics plays a significant role in regulating CYP2E1 hepatic activity. This
finding may have clinical relevance because CYP2E1 is responsible for the metabolism of
hepatotoxic substrates such as ethanol, acetaminophen, chlorzoxazone (CZ), pro-carcinogens
(benzene, chloroform, and N-nitroso-nicotine), and endogenous compounds such as estrogen,
acetone, and linoleic acid (Lieber 1997; Caro and Cederbaum 2004; Porubsky et al. 2008).
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Unlike other cytochrome P450s, human CYP2E1 is not functionally polymorphic and its reported
variants to date have no clinical or functional effects (Ingelman-Sundberg 2004b; Zanger and
Schwab 2013). CYP2E1 comprises 5.5–16.5% of the hepatic P450 pool (Zanger and Schwab
2013) and its substrate profile makes it relevant to older adults due to the detrimental and
unpredictable ADRs of these substrates. For example, CYP2E1 is inducible at heavy ethanol
intake which is responsible, along with Alcohol dehydrogenases (ADH), for the majority of
alcohol-mediated liver toxicity hospitalizations (Caro and Cederbaum 2004). In addition,
acetaminophen related liver injury is the primary over-the-counter drug-related hospitalization
(Lee 2017). Acetaminophen hepatotoxicity is mediated by the excessive formation of the toxic
byproduct N-acetyl-p-benzoquinone imine (NAPQI) and subsequent thiol residue depletion upon
acetaminophen overdose. CYP2E1 is responsible for NAPQI formation at high acetaminophen
doses, which highlights its importance in acetaminophen-induced liver damage (French 2013).
Finally, CZ is a high-risk drug listed on the 2019 American Geriatrics Society Beers criteria for
potentially inappropriate use in older adults. CZ is a centrally acting skeletal muscle relaxant that
is strongly recommended to avoid in the elderly due to moderate evidence of poor toleration by
this population according to these criteria. Taken together, these examples provide evidence for
clinical significance of the metabolism of drugs that are CYP2E1 substrates.
A limitation of the study as presented is that we could not manipulate epigenetic levels in
our post-mortem samples, so the association between epigenetics and drug metabolism is
correlational, rather than causal. Nevertheless, the use of the probe drug CZ renders the
association highly specific to the action of CYP2E1. In addition, sex differences in drug
metabolism have been described, however, our sample was comprised of only male mice. Hence,
female-specific effects should be investigated in future studies. Age-related changes to
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pharmacokinetic attributes such as plasma protein binding and hepatic blood flow should be the
subject of future in vivo investigations that pertain to drugs that are highly protein bound or have
high hepatic extraction ratio due to the possible changes to these attributes that affect the overall
disposition of drugs with advanced age (McLachlan and Pont 2012). Looking to the future, this
work may have clinical applications if extended to human populations. Age-related epigenetic
changes at human CYP2E1 and other drug metabolizing genes should be studied, and if these
changes are linked to altered clearance clinically, epigenetic biomarkers of altered drug
metabolism could be potentially used to guide dosing decisions in older adults. One potential
issue is that epigenetic modifications vary by cell and tissue type. Therefore, age-related effects
mapped in the liver will need to be tested for equivalency in peripheral cells or tissues (e.g.
blood) that are more readily accessible for the purposes of biomarker testing. However, prior
work by Horvath (2013) and others (Spiers et al. 2016; Zhu et al. 2018) suggests that many agerelated epigenetic changes are consistent across tissues and indeed in this study we demonstrated
continuity across mouse and human. Future work should investigate genome-wide epigenetic
changes with age in the liver and blood concurrently, for the same organism.
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Chapter 3: Histone acetylation at the sulfotransferase 1a1 gene is associated with its
hepatic expression in normal aging
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3.1.

Abstract

Phase II drug metabolism is poorly studied with advanced age and older adults may
exhibit significant variability in their expression of phase II enzymes. We hypothesized that agerelated changes to epigenetic regulation of genes involved in phase II drug metabolism may
contribute to these effects. We examined published epigenome-wide studies of human blood and
identified the SULT1A1 and UGT1A6 genes as the top loci exhibiting epigenetic changes with
age. To assess possible functional alterations with age in the liver, we assayed DNA methylation
(5mC) and histone acetylation (HAc) changes around the mouse homologs Sult1a1 and Ugt1a6
in liver tissue from mice aged 4-32 months obtained from the National Institute on Aging tissue
bank. Our liver sample shows significant changes to 5mC and histone 3 lysine 9 acetylation
(H3K9ac) around Sult1a1 but not at Ugt1a6 with age. Histone 3 lysine 27 acetylation (H3K27ac)
did not change with age at either locus. Sult1a1 gene expression is positively associated with its
H3K9ac levels but not with 5mC or chronological age. Our findings indicate that Sult1a1
expression is under epigenetic influence in normal aging, and that this influence is more
pronounced for histone acetylation than DNA methylation in this sample. In the future,
epigenetic biomarkers could prove useful to inform dosing regimens in older adults.
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3.2.

Introduction

Age-associated changes to hepatic phase II drug metabolism is poorly understood.
Recently, it has been suggested that epigenetic mechanisms could regulate genes encoding drug
metabolizing enzymes in older adults (Fisel et al. 2016). Aging is known to be associated with
extensive changes to epigenetic marks such as 5-methylCytosine (5mC) (Horvath and Raj 2018)
and, crucially, these changes are not purely stochastic. Several hundred loci in the genome
exhibit consistent 5mC changes in normal aging and these are known as age-associated
differentially methylated regions (a-DMRs). Many a-DMRs have functional consequences
(McClay et al. 2014; Horvath and Raj 2018), leading us to seek out a-DMRs at genes encoding
drug metabolizing enzymes to determine if they affect regulation of these genes. Previously, we
showed that a-DMRs at the cytochrome P450 2E1 gene, which encodes a phase I drug
metabolizing enzyme, showed significant changes with age that were associated with CYP2E1
function (Kronfol et al. 2020). In the current study, we extend this work to consider genes
encoding phase II (conjugation) drug metabolizing enzymes.
Data from epigenome-wide association studies (EWAS) in human blood have shown
significant changes to 5mC at several phase II genes with age (Heyn et al. 2012; Steegenga et al.
2014; Reynolds et al. 2014; Peters et al. 2015). However, the degree to which these a-DMRs are
present and affect gene expression in the liver, the primary site of drug metabolism, is unclear.
Therefore, the aim of this study is to identify age-related changes to 5mC and histone acetylation
at genes encoding phase II drug metabolizing enzymes in the liver and test if these epigenetic
changes are associated with gene expression. This study used liver tissue from mice aged under
controlled conditions, obtained from the National Institute on Aging tissue bank.
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We identified two phase II drug metabolism genes, SULT1A1 and UGT1A6, showing
strong evidence for a-DMRs in human blood studies (Table 3.1). We mapped the associated sites
in the human genome to their homologous mouse regions and tested for epigenetic changes at
these regions in mouse liver (Figure 3.1). High-Resolution Melt analysis of bisulfite-converted
DNA and chromatin immunoprecipitation assays was used to measure 5mC and histone posttranslational modifications respectively (Dozmorov 2015). We observed significant age-related
epigenetic change at the Sult1a1 gene and confirmed that this change was strongly associated
with its gene expression.
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Reference

SULT1A1
UGT1A6
UGT2B15
GSTT1
SULT2B1
UGT1A4
UGT1A5
UGT1A1
SULT1A3

Longevity Map (Human
Ageing Genomic Resources)
Exp

Peters et
al. 2015
Exp

Heyn et
Hannum et
al. 2012
al. 2013
Meth
Meth
Phase II genes

X

Horvath
2013
Meth

Reynolds et
al. 2014
Meth

Marttila et
al. 2015
Both

X
X

Steegenga et
al. 2014
Both
X

X
X

X
X
X
X

Table 3.1. Summary of human EWAS findings for phase II drug metabolism genes. Human ADME genes list from pharmaADME
(www.pharmaadme.org) was contrasted on the top findings from EWAS and gene expression studies of normal aging in human blood
DNA. Genes encoding phase II drug metabolizing enzymes that showed significant association in the top findings of these studies is
marked with an “X”. The total number of studies were a specific gene is a top association in the reported results is shown as a total in
the last column of the table. Exp: Expression, Meth: Methylation.

Total
3
2
1
1
1
1
1
0
0
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Figure 3.1 UCSC genome browser tracks showing (a) Mouse Sult1a1 gene location, H3K9ac,
H3K27ac occupancy, and ORegAnno regulatory elements. ORegAnno track shows identification
(ID) and transcription factor binding site (orange). Vertical bars highlighted in blue and green
represent the investigated regions in the High Resolution Melting, and Chromatin
Immunoprecipitation Quantitative Polymerase Chain Reaction assays respectively (full
coordinates in Table 3.2), and (b) The homologous genomic region in human showing SULT1A1
gene location, GeneHancer regulatory elements location and ID, and the identifier of the
significant CpG found in humans (blue bar).
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Primers (5’→ 3’)
Gene

Forward Primer

Reverse Primer

Product size/coordinates/assembly

High-Resolution Melt

CpG count

Sult1a1

GGAAGGTGTTTTTGTTTTTATG

CTAAAAATATATCTCTCCCAACT

134/chr7:133,820,382-133,820,515/mm9

1

Ugt1a6

AGTATGAAGGAGATAGTAGAATAT

AAAAAACCCATCAAAAAAACAC

206/chr1:90,035,169-90,035,374/mm9

4

Chromatin Immunoprecipitation Quantitative Polymerase Chain Reaction
Sult1a1

GGGGAACTCAGACAAACCAC

TCCTGCCCAGATACTGGTTC

154/ chr7:133,819,634-133,819,787/mm9

Ugt1a6

GCCACTCAGGAAGGACAGAG

GTGAGGCACTGGTCTGGTTT

153/ chr1:90,030,630- 90,030,782/mm9

Table 3.2. HRM and ChIP primers and qPCR product sequences. Primers used in the High-Resolution Melt and Chromatin
Immunoprecipitation Quantitative Polymerase Chain Reaction assays with size of PCR product, genomic coordinates, and assembly
with CpG count when appropriate.
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3.3.

Methods

3.3.1. Mice: Liver tissue samples from 20 male CB6F1 mice (5 subjects in each of four
age groups 4, 18, 24, and 32 months) were obtained from the National Institute on Aging (NIA)
tissue bank.
3.3.2. DNA and RNA extraction: Genomic DNA was extracted using the AllPrep
DNA/RNA kit (80204, Qiagen, Hilden, Germany) according to manufacturer’s protocol. DNA
and RNA purity and quantity were measured using a Nanodrop spectrometer (ThermoFisher,
Waltham, MA).
3.3.3. Selection of genomic regions of interest: Aging EWAS findings for human blood
were obtained from published studies (see Dozmorov 2015) and genes encoding drug
metabolizing enzymes were obtained from the ADME (absorption, distribution, metabolism, and
excretion) gene list from the pharmaADME consortium (pharmaADME.org), see Table 3.1. A
complete list of the genomic coordinates of all investigated regions in mouse can be found in
Table 3.2. Publicly available data from the mouse Encyclopedia of DNA Elements (ENCODE)
and Ludwig Institute for Cancer Research (LICR) chromatin immunoprecipitation (ChIP)
sequencing runs on young (8 weeks) male mouse liver tissue were used to identify two regions
with high levels of histone 3 lysine 9 acetylation (H3K9ac) and histone 3 lysine 27 acetylation
(H3K27ac) PTMs (GSM1000153, GSM1000140) (Figure 3.1).
3.3.4. Bisulfite conversion of genomic DNA and High-Resolution Melt (HRM) analysis:
200ng of liver genomic DNA was treated with sodium bisulfite according to the EZ DNA
Methylation kit protocol (Zymo Research, Irvine, CA). Mouse genomic DNA of 0, 5, 25, 50, 75,
and 100% methylation were used as standards (808060M, EpigenDx, Hopkinton, MA). High-
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Resolution Melt (HRM) assays using MeltDoctor reagents (Applied Biosystems, Foster City,
CA) on a Quantstudio 3 instrument were used to measure 5mC levels on the promoter and exon
2 of Sult1a1 and Ugt1a6 (Table 3.2). Samples were amplified by qPCR as follows 10min hold at
95ºC followed by 45 cycles of: 15sec at 95ºC, 60sec at 60ºC or 55ºC for Sult1a1 or Ugt1a6
respectively, followed by a melt curve stage. Each reaction included 20ng bisulfite-converted
DNA and final concentration of 1X MeltDoctor HRM MasterMix (Applied Biosystems), 0.2µM
forward and 0.2µM reverse primer (Table 3.2). The liver samples and the standards were run in
triplicate. The Net Temperature Shift values (Newman et al. 2012) of the liver samples were
interpolated on the standard curve to yield their 5mC percentage.
3.3.5. Gene expression analysis by reverse transcription – quantitative PCR (RT-qPCR):
Gene expression was measured for Sult1a1, Ugt1a6a and Ugt1a6b. We opted to measure the
gene expression of both isoforms of Ugt1a6 present in mouse liver because they are both
expressed from the same locus and the 5mC region investigated is shared among them. Hence,
allowing us to test for whether either isoform is affected by epigenetic changes if present. For
each sample, 1µg of total liver mRNA was reverse transcribed to cDNA by iScript kit according
to manufacturer’s protocol (Bio-Rad, Hercules, CA). Aliquots of cDNA were amplified in
triplicate using final concentration of 1X TaqMan master mix (Applied Biosystems) and 1X
TaqMan Sult1a1 or Ugt1a6a/b Mouse Gene Expression Assay (Mm01132072_m1,
Mm01967851_s1, Mm03032310_s1 ThermoFisher). qPCR conditions were as follows 2 min
hold at 50 ºC then 10min at 95 ºC, followed by 40 cycles of 15 sec at 95ºC and 60 sec at 60ºC.
Mouse Gapdh endogenous control was also assayed in triplicate (Mm99999915_g1,
ThermoFisher). Quantification cycles (Cq) were determined using the Relative Quantification
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application on the ThermoFisher Cloud. Normalized quantification cycles (ΔCq) were obtained
by subtracting the mean Gapdh Cq from the mean Cq of any of the genes.
3.3.6. Chromatin Immunoprecipitation Quantitative Polymerase Chain Reaction (ChIPqPCR): 80 mg of mouse liver per sample was processed using the TruChIP tissue shearing kit
(520237, Covaris, Woburn, MA). Minced tissue was fixed in 1% formaldehyde for 2 min,
washed, transferred to a tissueTUBE (Covaris), flash frozen in liquid N2 and pulverized. After
cell lysis, chromatin was sheared on a Covaris M220 for 8min. 2% of sheared chromatin per IP
was set aside as input control. ChIP used 5 µL of anti-H3K9ac (39137, Active Motif, Carlsbad,
CA), or 5µg of anti-H3K27ac (39133, Active Motif), or 5µg of Rabbit IgG isotype control
(ab171870, Abcam) incubated with 2µg sheared chromatin from each sample overnight (16
hours) at 4ºC. This mixture was added to Dynabeads Protein G (10004D, ThermoFisher) for 4
hours at 4ºC before washing and elution of ChIP DNA by heating to 65ºC for 1 hour. After
elution, samples were treated with RNAse and Proteinase K and DNA was purified using
QIAquick (28104, Qiagen).
Each ChIP’ed DNA was amplified in triplicate using PowerUp SYBR Green (Applied
Biosystems), with 0.2 µM of forward and reverse primers (Table 3.2) as follows: 2min at 50ºC,
2min at 95ºC followed by 45 cycles of: 15sec at 95ºC, 30sec at 58 ºC or 60ºC for Sult1a1 or
Ugt1a6 respectively and 1min at 72ºC, followed by melt curve stage. Cq values for each plate
were downloaded and the mean threshold cycle (Cq) obtained for each sample and normalized to
the dilution factor (2%=1/50) corrected Cq value (Log2 (50) =5.6438) of the input control to
obtain ΔCq. The percentage of input was calculated by multiplying 100 by 2ΔCq.
3.3.7. Statistics: Linear regression tests were conducted in R version 3.6.1 (www.rproject.org) with α=0.05.
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3.4.

Results

3.4.1. Age-associated changes to Sult1a1 and Ugt1a6 methylation and gene expression
DNA and RNA extractions from the mouse liver samples were successful with an
average 260/280 value of 1.94 [1.8-2.1] for DNA and 2.05 [1.94-2.1] for RNA. We tested for
epigenetic changes in mouse liver DNA using HRM. HRM analysis revealed that 5mC at
Sult1a1 decreases significantly with age (β=-1.08, 95%CI [-1.8, -0.2], SE=0.38, p=0.011)
(Figure 3.2 a) but did not change at Ugt1a6 (Figure 3.3 a).
The observed Sult1a1 promoter 5mC decrease with age translates to a 24% decrease in
the 32 months group versus 4 months groups. On the other hand, neither of Sult1a1 or Ugt1a6a/b
gene expression changed in a consistent manner with chronological age in this sample (p>0.05)
(Figure 3.2 b, Figure 3.3 c/d).
3.4.2. Histone acetylation analysis of Sult1a1 regulatory region
To assay histone acetylation levels in these regions, we used chromatin
immunoprecipitation coupled to quantitative PCR (ChIP-qPCR). We observed a significant
increase in H3K9ac at Sult1a1 (β= 0.11, 95%CI [0.002,0.22], SE=0.05, p=0.04) (Figure 3.2 c)
but not at Ugt1a6 when regressing ChIP-qPCR percentage of input on age (Figure 3.3 b). This
corresponds to a 0.11% increase in H3K9ac per month of increased age at Sult1a1. Furthermore,
H3K27ac levels were stable with age at both genes in this sample (Figure 3.2 c, Figure 3.3 b)
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Figure 3.2 Box plots with superimposed regression line (blue) of Age-Associated changes to
Sult1a1 (a) methylation (n=20), (b) gene expression (n=20), and (c) Histone 3 Lysine 27 and
Lysine 9 acetylation (H3K27ac and H3K9ac), chromatin Immunoprecipitation quantitative
polymerase chain reaction (ChIP-qPCR) data (n=20 per target), IgG percentage of input shows a
low background noise signal for each of the sample’s age groups. Data represent median (middle
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hinge), 25% (lower hinge) and 75% (upper hinge) quantile. Data points beyond upper or lower
1.5 * Inter Quantile Range are represented as individual black dots. (d) linear regression plot of
percentage of input of H3K9ac and Sult1a1 gene expression. (n=20 per locus) with reported
Adjusted R2 and p-value.
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Figure 3.3 (a) Box plot with superimposed regression line (blue) of age-associated changes to
Ugt1a6 methylation (n=20) (p>0.05). (b) Histone 3 Lysine 27 and Lysine 9 acetylation
(H3K27ac and H3K9ac), Chromatin Immunoprecipitation quantitative polymerase chain reaction
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(ChIP-qPCR) data (n=20 per target) (p>0.05), IgG percentage of input shows a low background
noise signal for each of the sample’s age groups. Data represent median (middle hinge), 25%
(lower hinge) and 75% (upper hinge) quantile. Data points beyond upper or lower 1.5 * Inter
Quantile Range are represented as individual black dots. Box plot with superimposed regression
line (blue) of age-associated changes to gene expression of (c) Ugt1a6a isoform and (d) Ugt1a6b
isoform (n=20 per locus) (p>0.05).
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3.4.3. Sult1a1 epigenetics and expression
As shown above, 5mC and H3K9ac levels at Sult1a1 changed with age. However,
Sult1a1 gene expression was not associated with chronological age. To determine if epigenetic
effects impacted Sult1a1 gene expression, we tested the degree of association between 5mC and
H3K9ac on Sult1a1 with its gene expression. H3K9ac changes on Sult1a1 intron1 are associated
with its gene expression (β=0.02, 95%CI [0.004,0.04], SE=0.008, p=0.018), explaining 23% of
the variability of the latter (Adj.R2=0.23, p=0.018) (Figure 3.2 d). However, 5mC at the Sult1a1
promoter did not associate with its gene expression (p>0.05, data not shown). This result
suggests that H3K9ac is a more robust independent predictor of gene expression of Sult1a1 than
5mC or chronological age.
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3.5.

Discussion

This study demonstrates that 5mC and H3K9ac levels change with age at Sult1a1 in
mouse liver. Furthermore, we showed that H3K9ac was significantly associated with Sult1a1
gene expression, while chronological age was not. This finding suggests that histone acetylation
levels may be a better predictor of drug sulfonation by Sult1a1 in advanced age than
chronological age itself.
Comparing our findings to published work, we found that Sult1a1 5mC levels diminished
with increasing age and this direction of effect supports prior observations in human blood
studies. For example, Reynolds et al. (2014) reported a hypomethylated CpG with age at human
SULT1A1 (Reynolds et al. 2014) overlapping the homologous mouse region investigated in this
study. Furthermore, Fu et al. (2012) reported increased Sult1a1 expression in mouse liver tissue
aged 27 months compared to 3 months, as detected via RT-qPCR (Fu et al. 2012). This suggests
that increases to Sult1a1 gene expression could occur with age but require more power through
larger sample sizes to be reliably detectable. On the other hand, age-related changes to 5mC and
H3K9ac were detectable at Sult1a1 in this study’s sample and H3K9ac is associated with its gene
expression to a substantial degree of 23%. Prior studies of histone PTM changes in the context of
aging are limited and we are not aware of existing data for Sult1a1 in the liver. Schroeder et al.
(2013) found that histone deacetylase inhibitors influenced gene expression of Sult1a1 in specific
brain regions, prefrontal cortex and nucleus accumbens, of mice suggesting that histone
acetylation affects expression, but this study did not examine the effect of aging nor changes in
the liver (Schroeder et al. 2013).
This finding may have clinical relevance because the SULT1A1 enzyme is involved in
the sulfonation of drugs including tamoxifen and estrogen replacement therapies (Glatt et al.
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2001). SULT1A1 comprises the majority, 53%, of the total hepatic sulfotransferase (Riches et al.
2009) and its substrate profile makes it relevant to older adults because these substrates are
indicated for the treatment of age-related disease or have detrimental and unpredictable
toxicities. For example, SULT1A1 activates the prodrug tamoxifen which is essential for its antiestrogen activity in the treatment of breast cancer (Brauch et al. 2009). In addition, prior studies
have implicated genetic sequence variants at SULT1A1 in response to estrogen-replacement
therapy (Rebbeck et al. 2006; Hildebrandt et al. 2009). Therefore, it is conceivable that agerelated functional epigenetic changes at SULT1A1, as shown here, may similarly affect response
to estrogen-replacement therapy. This suggests an area of future clinical study in humans.
A limitation of the study is that we could not directly manipulate epigenetic levels in our
post-mortem samples, so the relationship between epigenetics and gene expression is
correlational, not causal. Also, sex differences in metabolism have been reported, but our sample
was comprised of only male mice. Hence, female-specific effects should be inspected in
forthcoming studies. Age-related epigenetic changes at human SULT1A1 should be studied, and
if these changes are connected to altered clearance clinically, epigenetic biomarkers of altered
drug metabolism could be potentially used to guide dosing decisions in older adults.
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3.6.

Study Highlights

What is the current knowledge on the topic?
The determinants of age-related changes of drug response due to phase II metabolism is poorly
understood. The study of epigenetic regulation of ADME genes is in its infancy and no reports
correlate age-related changes to epigenetic regulation of genes controlling phase II metabolism.
What question did this study address?
What is the extent of age-related change of DNA methylation and histone acetylation at the
Sult1a1 and Ugt1a6 genes? What is the extent of association of these epigenetic marks with gene
expression?
What does this study add to our knowledge?
Determine the extent of change to DNA methylation and histone acetylation on sulfonation gene,
Sult1a1, and its degree of association with its gene expression in advanced age. This study
reports a lack of change to age-related epigenetic regulation on glucuronidation gene, Ugt1a6, in
mouse liver.
How might this change clinical pharmacology or translational science?
This might stimulate clinical work that determines how we dose older patients based on
epigenetic levels at genes controlling phase II metabolism to optimize drug response and
decrease adverse events.
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Chapter 4: Cross tissue correlation of Cyp2e1 and Sult1a1 methylation levels in mice

4.1

Abstract

Epigenetic levels vary by tissue type, yet the degree of variation shared between tissues is
less established. The relationship between blood methylation and methylation in organs that
express phase I and II metabolism genes is not well characterized. We hypothesized that blood
DNA methylation (5mC) levels of genes involved in drug metabolism are correlated with those
of the liver and the brain. We recently identified the cytochrome P450 2E1 (Cyp2e1) and
sulfotransferase (Sult1a1) genes as top mouse ADME loci exhibiting epigenetic changes with
age. To investigate the extent of association between methylation levels of Cyp2e1 and Sult1a1
in blood and organs that express those genes, we obtained liver, blood, hippocampus, and cortex
from mice aged 5 months from the Jackson Laboratory. We then assayed 5mC using HighResolution Melt assays, around mouse Cyp2e1 and Sult1a1 from these tissues. 5mC of mouse
livers exhibit significant negative correlation with that of blood at both genes. However, blood
5mC of neither gene was significantly associated with 5mC in the cortex nor hippocampus brain
regions. This suggests that epigenetic levels in blood 5mC may inversely reflect those in the liver
for Cyp2e1 and Sult1a1 genes. This study could serve as the starting point of future in depth
studies that explicitly looks at blood based 5mC as a proxy to infer the status of methylation on
Cyp2e1 and Sult1a1 in the liver.
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4.2

Introduction

Tissue-specific patterns of DNA methylation are recognized to be highly discordant (Bird
2002; Zhang et al. 2013; Dmitrijeva et al. 2018). Although significant differences in mean levels
of 5mC between tissues exist, they should not be used to imply a lack of relationship between
these marks. Studies have shown that cross-tissue patterns of 5mC can be used to predict a
singular outcome such as mortality, disease risk, or longevity (Horvath and Raj 2018), indicating
a mutual underlying process influencing 5mC levels across tissues, however with different
nuances. We aimed to test this cross-tissue correlation around two genes encoding drug
metabolizing phase I and II enzymes, Cyp2e1 and Sult1a1 respectively, which have been
previously shown to be influenced by epigenetic regulation with age (see Chapters 2, 3 and
Kronfol et al 2020).
Changes to hepatic 5mC at Cyp2e1 are associated with changes to gene expression levels
(Kronfol et al 2020). Furthermore, the regions that we tested were known a-DMRs in human
blood. However, the degree to which these changes, or lack thereof, in 5mC are present in other
tissues is unknown. These considerations led us to hypothesize that the variability of hepatic
5mC could be associated with that of 5mC from whole blood or other tissue that show high
expression of these genes such as the brain, specifically the cortex and hippocampus. In this
study, we aimed to test for the degree of association between 5mC levels in the liver, whole
blood, hippocampus, cortex, and whole brain in young male C57BL6J mice. Through this
investigation we set out to measure the extent and nature of association between 5mC levels on
Cyp2e1 and Sult1a1 in organs that exhibit high expression of those genes and whole blood.
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4.3.

Method

4.3.1. Sample
All procedures were conducted according to the Institutional Animal Care and Use
Committee (IACUC) protocol (AD10002047) approved by Virginia Commonwealth University.
8 male C57BL/6J were purchased from the Jackson Laboratory. Animals were housed in groups
of 4 and maintained in controlled conditions of 21°C and a 12-h light/dark cycle in microbe free
environment. Animals were fed standard chow as needed. Animals were healthy and showed no
signs of aggression or harm. Blood samples were obtained from the submandibular vein prior to
sacrifice. Animals were sacrificed by decapitation without anesthesia, because this could
interfere with epigenetic marks. The age of the animals was 5 months at the day of sacrifice. The
hippocampus and the cortex were dissected from the brain and the remainder was kept as a
whole and analyzed as “rest of brain”. The hippocampus, cortex, rest of brain, liver, and 100µL
whole blood mixed with 1% EDTA were collected from each animal and flash frozen in liquid
N2 and stored in -80°C until day of analysis.
4.3.2. DNA extraction and bisulfite conversion
Genomic DNA (gDNA) was extracted using DNeasy Blood and Tissue kit (69506,
Qiagen) according to manufacturer’s recommendations. Bisulfite conversion was performed on
250 ng of gDNA using the EZ DNA methylation kit (D5001, Zymo Research). Single stranded
DNA quantity and quality were measured by Nanodrop spectrophotometer.
4.3.3. High-Resolution Melt (HRM) assays
HRM assays were performed as previously described for Cyp2e1 and Sult1a1 (Kronfol et
al). Briefly, 20 ng of bisulfite converted DNA was amplified on Quantstudio 3 using MeltDoctor
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reagents (Applied Biosystems), 0.2µM forward and 0.2µM reverse primer. For primer and
product sequence refer to Table 2.2 and Table 3.2. Samples were amplified by qPCR as follows
10min hold at 95ºC followed by 45 cycles of: 15sec at 95ºC, 60sec at 60ºC or 57ºC for Sult1a1
or Cyp2e1 respectively, followed by a melt curve stage. The High-Resolution Melt assays
measured the methylation of 7 and 1 CpG levels for Cyp2e1 and Sult1a1 regions respectively.
The Net Temperature Shift values (Newman et al. 2012) of the all samples were interpolated on
the standard curve to yield their 5mC percentage. A standard consisting of 0, 5, 10, 25, 50, 75,
and 100% methylated mouse genomic DNA was included on each plate (EpigenDx). Both the
standard and the test samples were run in triplicates.
4.3.4. Statistics
Pearson correlation tests were conducted in R version 3.6.1 (www.r-project.org) with
α=0.05.
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4.4.

Results

4.4.1. Cyp2e1 tissue-specific methylation and cross-tissue correlation
The mean 5-MethylCytosine (5mc) levels of Cyp2e1 in descending order were as follows
whole blood (93.5%), rest of brain after hippocampus and cortex were removed (66.3%), cortex
(53.7%), hippocampus (43.5%), and liver (9.3%) (Figure 4.1 a). 5mC typically exerts a
repressive influence on gene expression; therefore, we should expect the inverse of this pattern
of descending order for expression in these tissues. This is broadly the case, with Cyp2e1 tissuedependent gene expression being highest in liver and lowest in blood, with the brain as an
intermediate (Figure 4.2 a). Cyp2e1 5mC levels derived from whole blood were negatively
correlated with those from the liver (r= -0.35, p=0.03) but not with 5mC levels of any of other
tissues (p>0.05) (Figure 4.1 a). This indicates that an inverse relationship exists between Cyp2e1
5mC levels in the liver and those of whole blood.
4.4.2. Sult1a1 tissue-specific methylation and cross-tissue correlation
The mean 5mC levels of Sult1a1 in descending order were as follows whole blood
(75%), rest of brain regions (50.3%), liver (39.6%), hippocampus (23.3%), and cortex (22.4%)
(Figure 4.1 b). This pattern, however, does not resemble that of Sult1a1 tissue-dependent gene
expression indicating that additional factors regulate tissue-specific gene expression of Sult1a1
than 5mC alone (Figure 4.2 b). 5mC levels derived from liver Sult1a1 were positively correlated
with those in the rest of brain (r=0.71, p= 0.03), negatively with blood (r= -0.16, p=0.04), but not
with the 5mC levels of the other brain regions tested (p>0.05) (Figure 4.1 b). In addition, blood
5mC levels were negatively correlated with the rest of brain (r= -0.35, p= 0.02) (Figure 4.1 b).
Overall, these results indicate an inverse relationship exists between 5mC levels in the liver and
whole blood for Sult1a1. However, the relationship between blood and liver seems weaker than
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that of blood and brain. Therefore, blood Sult1a1 5mC measurements are most accurate
predictors of that of brain regions, excluding the cortex and hippocampus, followed by the liver.

Figure 4.1. Boxplot of DNA methylation percent (DNAm) across the liver, rest of brain, cortex,
hippocampus, and whole blood arranged in descending order and Correlation matrix reporting
Pearson correlation statistical test result (r) for either (a) Cyp2e1 (N=40, n=8) or (b) Sult1a1
(N=40, n=8). White blank cells indicate non-significant association (p>0.05). Refer to Table 4.1
and 4.2 for individual p-values of each Pearson correlation test of a given pair. Color gradient

102

indicates the direction of effect of the association with dark red representing the strongest
positive association of 1 while dark blue representing the strongest negative association of -1.
Only lower half of the plot is shown to prevent redundancy in reporting the results.

Figure 4.2. Violin plot showing average expression of either (a) CYP2E1 or (b) SULT1A1
across liver, whole blood, hippocampus, and cortex. Data obtained and plotted from GTEx
Analysis Release V8 (dbGaP Accession phs000424.v8. p2). TPM: Transcripts Per Million.
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Blood
Rest of Brain
Cortex
Hippocampus
Liver

Blood
0
0.1027
0.5319
0.1405
0.0301

Rest of Brain

Cortex

Hippocampus

Liver

0
0.9417
0.2067
0.1374

0
0.2323
0.9634

0
0.4397

0

Table 4.1 Cyp2e1 P-values for each pair of tissue types

Blood
Liver
Hippocampus
Cortex
Rest of Brain

Blood
0
0.0423
0.2947
0.9754
0.0258

Liver

Hippocampus

Cortex

Rest of Brain

0
0.1223
0.7008
0.0399

0
0.1884
0.0899

0
0.5042

0

Table 4.2 Sult1a1 P-values for each pair of tissue types
Significant p-values (p<0.05) are highlighted in red
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4.5.

Discussion

We previously determined the extent and direction of effect of age-related changes to
5mC levels at Cyp2e1 in the liver (Kronfol et al 2020). Here, we expanded our understanding of
tissue-specific variation to 5mC in not only peripheral tissue (whole blood), but also the different
regions of the brain that have significant expression of Cyp2e1 and Sult1a1. Furthermore, we
showed that variation in 5mC levels of Cyp2e1 and Sult1a1 in the liver are inversely reflected in
5mC levels at these genes in whole blood. The size of the inverse correlations was relatively
large (approximately -0.3). This work confirms a relationship between 5mC levels at these two
genes in different tissues of the same subject and could pave the way for similar studies in
humans.
Considering our findings in terms with previous work, we found equivalent levels of
5mC as previously reported in mouse liver (Kronfol et al 2020) and blood (Peters et al 2015). In
addition, for Cyp2e1, our data suggest that only 5mC levels in the liver are correlated with 5mC
levels in blood. 5mC from other specimens (DNA from buccal or nasal swab, etc) should be
investigated for correlation with that of different brain regions. For Sult1a1, the data suggest
blood-derived 5mC is more correlated with 5mC of the brain, excluding the hippocampus and
the cortex, than with the liver. In addition, tissue-specific gene expression of Sult1a1 might be
influenced by other factors than 5mC alone. Histone post translational modifications could also
play a role, but these do not function well as biomarkers because they must be assayed from
fixed chromatin, not DNA that is more readily available.
A limitation of our study, in the context of the broader substantive focus of this
dissertation, is that we did not study how cross-tissue 5mC correlations change with age. Given
the negative correlation between 5mC levels in blood and liver on Cyp2e1 in young age, we can
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predict that any age-related change may also be negatively correlated. Such that if we see agerelated hypermethylation in the liver, we will see hypomethylation in blood. In addition, we
typically see regions that are constitutively methylated at young age, like blood 5mC in this case,
become hypomethylated due to epigenetic drift and attrition with age (Issa 2014; Jones et al.
2015; Zhu et al. 2018). Nonetheless, this study explicitly looked at the lower end of the mouse
adulthood of an age of 5 months and the data should serve as a reference for future investigations
of the relative baseline levels of 5mC in the brain, liver, and blood at older ages.
Limitations of this study include the exclusion of female mice. However, we anticipate
that this should be included in future, larger studies. Studies intended to examine a wider range
of the adult life of mice could be performed, or similar studies could be attempted for humans if
DNA from multiple tissues (e.g. blood, liver) can be obtained from the same individuals. This
may be possible from some biobanks. Finally, more work is needed to establish whether the
extent of the relationship between 5mC on drug metabolism genes in blood and liver can be
clinically useful as a proxy to guide drug dosing decisions.
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Chapter 5: Method optimization of Reduced Representation Bisulfite Sequencing (RRBS)
for genome-wide analysis of mouse liver DNA methylation

5.1.

Abstract

DNA methylation is the most widely studied epigenetic mark to date. Several methods
have been proposed to aid the accurate measurement of DNA methylation in the context of
Cytosine-Phosphate-Guanine (CpG) positions in mammalian genomes. However, few have been
adopted and implemented for different applications as much as reduced representation bisulfite
sequencing (RRBS). RRBS has been widely used to optimize DNA methylation detection from
tissues and cells, yet few methodologies expand the sequencing library preparation portion of
RRBS. We proposed to augment the RRBS protocol using a commercially available Adaptase
library technology to create optimized library complexity intended for the detection of CpG
DNA methylation from mouse liver tissue belonging to young (4 months) and old ages (32
months). We report that this optimization produced high yields of RRBS libraries with consistent
DNA fragment distributions between both ages and high proportions of shared number and
positions of Cytosines assayed per age. We first start with the same procedure of column-based
DNA extraction that is then enzymatically cut by Msp I, a methylation indifferent restriction
enzyme. However, we perform DNA fragment size-selection of 100-220 bp followed by bisulfite
conversion to this cut DNA before initiating the Adaptase library preparation protocol.
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5.2.

Introduction

Reduced Representation Bisulfite Sequencing (RRBS) is a robust method for detecting
methylation and has been carried out by researchers for more than a decade and cited over 800
times (Meissner et al. 2005). We propose to optimize the current technique by coupling it with
the Adaptase advanced library amplification technology for the detection of CpG DNA
methylation obtained from mouse liver tissue. This method optimization effort will serve as the
primary assay for a larger aging epigenome-wide association study by our group. We focus on
DNA methylation because it is the best-characterized epigenetic mark, both overall and in the
context of aging.
Our method of choice, RRBS, is robust and cost-effective, providing good coverage of
CpGs in genes and regulatory regions (Gu et al. 2011). RRBS is not new, however, its
application to aging and drug metabolism is highly innovative, because future findings may shed
light on mechanisms of aging and open new avenues of research into novel biomarker strategies.
We propose to use RRBS specifically for several reasons. Genome-wide DNA methylation
analysis is typically carried out using microarrays or next generation sequencing (NGS) (Rakyan
et al. 2011). Methylation arrays for humans are excellent, with the Illumina Infinium capable of
measuring 5mC at ~850,000 loci. However, there are no equivalent arrays for mice. The best
option we are aware of is the Mouse CpG Island Microarray from Agilent, which can assay
~90,000 loci, much less than the human arrays. However, the extent of genome-wide coverage
offered by arrays of any kind is poor relative to Next Generation Sequencing (NGS). The goldstandard for genome-wide DNA methylation analysis is whole genome bisulfite sequencing
(WGBS) (Lister et al. 2009; Rakyan et al. 2011). Here, the entire genome is subjected to bisulfite
treatment and sequenced to high depth of coverage, providing single base resolution of
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methylation. This makes it very attractive, but it is still too costly for the large numbers of
samples required for association studies. RRBS, one the other hand, is an excellent compromise.
Using enzymatic digestion at CpG sites followed by fragment size selection, the sequencing
libraries are enriched for regions of the genome with high CpG density, which are often
important regulatory regions. By trading full genome-wide coverage for high-resolution at these
important loci, RRBS requires just ~20 million reads per sample, thereby enabling sufficient
numbers to be assayed for an association study (Gu et al. 2011).
We focused on 5-methylCytosine (5mC) instead of other DNA modifications for various
reasons. Although other DNA modifications have been discovered, 5-hydroxymethylcytosine
(5hmC) (Kriaucionis and Heintz 2009; Pastor et al. 2011) or 5-formylcytosine (5fC) (Bachman et
al. 2015), the role of 5mC in cell differentiation and regulation is the best-characterized, meaning
that 5mC results are more readily interpretable. Furthermore, the bisulfite sequencing approach
(RRBS) (Meissner et al. 2005; Gu et al. 2011) that we intend to optimize works by converting
unmethylated cytosines to uracils via sodium bisulfite treatment (which then convert to thymines
in PCR) (Frommer et al. 1992).
Previous epigenome-wide association studies of liver tissue have used RRBS methods
that prepare sequencing libraries in a conventional way (Hahn et al. 2017; Stubbs et al. 2017).
However, a recent systematic evaluation of library preparation methods by Li et al ((Zhou et al.
2019) shows that the new Adaptase technology outperforms traditional library techniques. The
authors conclude that libraries prepared by Adaptase achieve the highest proportion of CpGs
assayed, most effective sequencing coverage, and lowest proportion of low-quality reads. No
published reports utilize this new technology for liver RRBS. Therefore, we wanted to
implement the Adaptase method in the RRBS protocol for liver DNA. We took this novel
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method to see how it performs in test samples and obtain quality control information. Briefly, the
Adaptase enzyme maximizes the recovery of low concentrations of single stranded DNA by
ubiquitous ligation and priming by universal tags. This ensures successful subsequent
amplification of all DNA fragments. Thus, preserving DNA information and library complexity.
We subjected 600 ng of genomic DNA from mouse liver to DNA methylation analysis by
RRBS using the commercially available Adaptase technology in the ACCEL NGS Methyl-Seq
Kit (Swift Bioscience). This involved Msp I digestion of DNA, size-selection, bisulfite
conversion, simultaneous tailing and ligation by Adaptase of all single stranded DNA fragments,
3’extension, bottom strand ligation, and finally unique sequencing adapter ligation through PCR
amplification to produce the final sequencing library (Figure 5.1). Library size distribution and
integrity was validated using the high-sensitivity DNA chip on an Agilent BioAnalyzer.
Multiplexed pair end 150bp sequencing was carried out on an Illumina HiSeq 4000 at the
GeneWiz service provider sequencing facilities. We carried out NGS on 4 test samples. We
aimed to exceed the recommended 20-25 million reads needed to obtain enough coverage depth
for accurate methylation measurement.
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Figure 5.1. Schematic representation of the seven steps of the optimized RRBS protocol.
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5.3.

Method

5.3.1. Sample
Genomic DNA was obtained from 20 mg liver tissue of 4 months old sample and a 32
months old sample using the AllPrep DNA/RNA kit (Qiagen). DNA quality and quantity were
measured on Nanodrop spectrophotometer (ThermoFisher) and Qubit 4.0 (ThermoFisher)
respectively.
5.3.2. Reduced Representation Bisulfite Sequencing (RRBS)
RRBS libraries were prepared as previously described (Gu et al. 2011) with slight
modifications. 600 ng genomic DNA was cut enzymatically by Msp I (R0106T, New England
Biolabs, Ipswich, MA) overnight (16hrs) at 37 °C, then purified the next day by QIAquick PCR
purification kit (Qiagen). The purified Msp I digested DNA was run on a 2% ethidium bromide
agarose gel adjacent to a paired lane of genomic DNA of the same sample to check for
successful Msp I digest. Unsuccessful digests were repeated. The sample was size selected for
fragments between 100-220 base pair (bp) long using the 2% ethidium-free agarose gel cassette
(CEF2010, Sage Science, Beverly, MA) on a Pippin Prep machine. The Pippin Prep protocol was
set to the “Range” collection mode and reference lane 3 was used for the provided marker E.
Samples were collected from the elution module using 40µL of provided electrophoresis buffer.
The size selected Msp I digested DNA was bisulfite converted by the EZ DNA methylation kit
(D5001, Zymo Research, Irvine, CA) according to manufacturer’s recommendation. Briefly,
samples were incubated at 37 °C for 15 min followed by overnight (16hrs) incubation with
100µL of provided CT conversion reagent at 50 °C to allow the deamination process of
unmethylated cytosines into uracils to occur. Samples were eluted in a final 10µL elution buffer.
2 µL was used to measure the concentration of the samples using the ssDNA Qubit assay
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(Q10212, ThermoFisher). Samples with concentration below detection range were repeated.
Finally, about 3 ng of Msp I digested, size-selected, and bisulfite converted DNA was used as
input for the ACCEL-NGS Methyl-Seq DNA Library kit (30024, Swift Bioscience) to create the
RRBS libraries.
Briefly, 8µL of sample was mixed with provided low EDTA TE buffer q.s 15µL and
incubated at 95 °C for 2min and then placed on ice, spun down and added to 25µL of Adaptase
reaction mixture. The Adaptase reaction mixture components are 11.5µL of low EDTA TE, 4 µL
each of provided Buffer G1 and Reagent G2, 2.5 µL Reagent G3, and 1 µL each of Enzyme G4,
5, and 6. The mixture was incubated at 37 °C for 15 min, then at 95 °C for 2 min. The samples
were kept on ice followed by the addition of 44 µL of Extension Reaction mixture containing the
following, 2 µL Reagent Y1, 42 µL Enzyme Y2. The samples were mixed and incubated at 98°C
for 1 min, followed by 62 °C for 2 min and 65 °C for 5 min and a 4°C hold. The samples were
then cleaned up from reaction components using 134 µL of SpriSelect beads (Beckman-Coulter).
The samples were eluted in 15µL low EDTA TE and added to 15µL of the Ligation mixture. The
Ligation mixture contained 3 µL Buffer B1, 10 µL Reagent B2, 2 µL Enzyme B3. The samples
were incubated at 25 °C for 15min. The samples were cleaned up from reaction components with
42 µL beads. The samples were eluted in 20 µL low EDTA TE buffer. 5 µL of unique index
from Methyl-Seq Set A indexing kit was used per sample (36024, Swift Bioscience). Each of the
young and old sample was run twice with different indices. 25 µL of PCR reaction mixture was
added that contained the following 10 µL low EDTA TE buffer, 10 µL Buffer R1, 4 µL Reagent
R2, 1 µL Enzyme R3 and allowed to amplify on Proflex thermal cycler (Applied Biosystems).
PCR conditions were as follows 98 °C for 30 sec followed by 10 cycles of 98°C for 10sec, 60°C
for 30sec, 68°C for 60sec, and a final hold at 4°C. PCR reaction was cleaned up twice with 50µL
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of SpriSelect beads following manufacturer’s recommendation for libraries intended for
sequencing on patterned flow cells such as HiSeq4000. Final libraries were eluted in 22µL low
EDTA TE and 1µL was used to measure concentration using the DS DNA Qubit assay
(ThermoFisher). 1µL was used to trace the size-distribution and average library size on the HS
DNA chip on Agilent 2100 Bioanalyzer. Libraries were sequenced pair ended 150 bp on
Illumina HiSeq4000 using 5% Phi-X spike-in (as positive control for successful sequencing run)
by GeneWiz service provider. Each RRBS sample yielded a single Fastq file. The reverse reads
were discarded.
5.3.3. Data processing
Sequencing reads (FASTQ files) were mapped to the mouse genome (mm10) and
methylation calls are made using Bismark (Krueger and Andrews 2011), which is based on Bowtie
(Langmead and Salzberg 2012). Bismark yielded for each RRBS sample a quality control file and
one coverage file per sample with CpG position and methylation information, expressed as
unmethylated and methylated reads at each CpG.
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5.4

Results

5.4.1. DNA extraction, MspI digestion, and fragment isolation
DNA extraction from the mouse liver samples was successful with mean DNA
concentration of 120 ng/µL with an average 260/280 value of 2.0 [1.93-2.06]. 600 ng of genomic
DNA was enzymatically cut with MspI and was size selected for fragment between 100-220 bp,
which gave the highest resulting yield of 0.5-1% w/w, which was within expected range
(Meissner et al. 2005).
5.4.2. RRBS library preparation and Quality control
3ng was used as input for library preparation. Library amplification was successful with a
final library concentration of 12.9 ng/µL for an average of 258 ng per sample. Average library
size and molarity was 301 bp and 63.6 nMol respectively. Our RRBS library distribution shows a
unique pattern of three distinct peaks similar to those previously reported. Three unique peaks at
259, 282, and 316 bp were present in the BioAnalyzer trace of the RRBS libraries (Figure 5.2).
Each peak represents high abundance of fragments of similar fragment sizes. This peak profile is
a characteristic of enzymatically digest DNA fragment by MSP I.
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Figure 5.2. Representative RRBS library trace. Showing peaks distinct to RRBS libraries at 259,
282, 316 bp. X-axis is Arbitrary fluorescence units [FU], y-axis is fragment size in base pair
[bp]. A peak at 35 and 10380 bp indicate the lower and upper ladder marks for the High
sensitivity 2100 BioAnalyzer assay.
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Age (months)
4
4
32
32

Sample ID
4-11 replicate 1
4-11 replicate 2
32-15 replicate 1
32-15 replicate 2

Index
I4
I2
I5
I16

Index sequence
TGACCA(AT)
CGATGT(AT)
ACAGTG(AT)
CCGTCC(CG)

Table 5.1. Summary table reporting chronological age (months) and ID of each sample,
index and index sequence used.

Age (months)

Total number of reads

4m rep1
4m rep2
32m rep1
32m rep2

37,014,015
54,032,672
57,122,708
41,196,659

Total number of
Unique Alignments
19,576,596
27,520,231
28,007,798
16,898,265

Proportion of
Unique Alignments
0.549
0.509
0.490
0.410

Table 5.2. Summary table reporting average total number of reads and total number of
Unique Alignments per age (months)
Age (months)
4m rep1
4m rep2
32m rep1
32m rep2

Number of Cytosines
assayed post-QC
1,048,263
1,171,890
1,176,430
1,050,249

Cytosines in common
across 2 replicates

Proportion in common
across 2 replicates

1,029,626

0.982

1,026,686

0.978

Table 5.3. Summary table reporting number of unique cytosines captured per replicate
after quality control (n reads per cytosine: 10 < C >300)

5.4.3. Next Generation Sequencing (NGS) data
Bismark was run according to default settings for RRBS fastq files (Krueger and
Andrews 2011). Reference mouse genome used was mm10. Bismark output included a summary
file and a methylation coverage file per sample. Total sequences analyzed for each replicate of
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the 4 and 32 months samples respectively are shown in Table 5.2. Reads with unique alignments
per sample ranged from 16.9M to 28M per sample/replicate (Table 5.2). The percentage of
unique alignment to total sequence analyzed was approximately 50% for 3 of the 4 samples.
These values improve upon previously reported results from traditional RRBS (Chatterjee et al.
2012). while replicate 2 of the 32 month sample was somewhat lower at 41% and this made the
average percentage alignment for the 32 month samples somewhat lower (Figure 5.3 a). Quality
control (QC) of cytosine position coverage was set at the levels used by Stubbs et al. whereby
sites with 10 or fewer reads and those with 300 or more reads are discarded. Despite replicate 2
of the 32 month sample having least aligned reads (Table 5.2), the number of Cytosine positions
with good data, i.e. 1,050,249 after QC, was still slightly more than for replicate 1 of the 4 month
sample (Table 5.3). Overall, despite the number of uniquely aligned read numbers differing by a
factor of 1.6 across the samples, the number of Cytosine positions passing QC was remarkably
similar. Most importantly, replicates returned high quality quantitative information for almost the
same sets of approximately 1 million Cytosine positions (98% the same) despite there being
approximately 20 million CpGs in the mouse genome. This showed that the replicates were
highly consistent in the regions of the genome they captured.
The percentage 5mC (in CpG context) was 37.25 and 33.85 % for the 4 and 32 months
respectively (Figure 5.3 b). The percentage of non CpG methylation detected was about less
than 1.5 % for both ages. This data suggests that the sequencing of the RRBS libraries was
successful with equivalent numbers of total cytosine detected for both ages. However, a clear
decrease in the CpG methylation calls was present in the 32 months (old) age compared to the 4
months (young) age. This effect direction mirrors that observed using ELISA global assay in
previous section of this dissertation (see Chapter 2 Figure 2.6)

118

Figure 5.3. Bar plot of data from Bismark quality report showing (a) Percentage of total and
unique alignments per age and (b) CpG methylation percent per age.
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5.5.

Discussion

We previously initiated a set of studies investigating liver specific methylation changes
with age at candidate genes involved in phase I and II metabolism. Our studies were based on a
gene selection approach identified from large epigenome-wide association studies in human
blood. Indeed, these studies demonstrated, to the best of our knowledge, the first evidence of the
influence of age-related epigenetics changes on the pharmacokinetics of drug metabolizing
enzymes. However, several other genes from these human studies showed varying degree of
evidence of change with age. An estimated one third of all genes involved in ADME processes
show various levels of association with age (Dozmorov 2015). Therefore, optimization of a
highly reproducible method for the genome-wide quantitation of epigenetic marks at regions of
regulatory importance was warranted. We demonstrated in this study the feasibility of using
RRBS to quantify 5mC from mouse liver DNA of old and young age that can be leveraged to
larger epigenome-wide aging studies. This is an ongoing effort in our lab, where we will attempt
to elucidate the degree of age-related variation of 5mC on genes controlling the attributes of
mouse hepatic metabolism on a genome-wide basis.
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Chapter 6: Overall Conclusions and Future Directions

Through this work we have demonstrated a novel approach for answering an overarching
question of what additional determinants of biological variability are affecting drug metabolism
in advanced age. Our hypothesis that epigenetic mechanisms such as DNA methylation and
histone modifications influence drug metabolism with age was warranted in order to set the stage
for new technologies to overcome the limitations of current tools used in the clinic that guide
drug dosing decisions in the older adult population. We aimed to elucidate the nature of the
relationship between epigenetic dysregulation and the function of drug metabolizing enzymes in
advanced age. In fact, we were able to define the continuity of the relationship from DNA to
function in a unique set of experiments that, to the best of our knowledge, have not been pursued
before. In addition, this work described the influence of epigenetics on genes encoding both
phase I and II metabolizing enzymes. We show that both phases are under the influence of agerelated epigenetic change with varying degrees and through shared and distinctive mechanisms.
For phase I, we showed that the Cyp2e1 gene is under the influence of age-related changes to
5mC and histone acetylation (H3K9ac). The degree of effect on the downstream function of
CYP2E1 is substantial for both epigenetic marks. On the other hand, while 5mC and H3K9ac
levels at the Sult1a1 phase II metabolism gene changed with age, only H3K9ac was shown to
influence expression.
Epigenetic modifications have demonstrated clinical usefulness through successful
examples, such as the use of DNA methylation as a clinical biomarker to guide drug selection.
For example, MGMT methylation status is now being used clinically to guide treatment selection
for glioma multiforme patients. We believe DNA methylation could be utilized in the clinic as a
clinical biomarker to guide drug dosing decisions for older adults. Although H3K9ac was a
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better predictor of function for both Cyp2e1 and Sult1a1, it is difficult to conceive of histone
modifications being used as clinical biomarkers using the methods we employed here (chromatin
immunoprecipitation). Alternative, novel methods that are more rapid and robust will be needed
before histone acetylation can see widespread use as a clinical biomarker.
DNA methylation is easy to obtain from peripheral tissue such as blood. Here, we
demonstrated correlations between levels of 5mC in the liver for Cyp2e1 and Sult1a1 and those
in whole blood. These relationships suggest that blood-based biomarkers may reflect hepatic
5mC levels and these may be useful to guide drug dosing in the future. However, significant
additional work in humans will be necessary to demonstrate the feasibility of this innovation.
The work as presented here serves as a first step towards future research aimed at
evaluating the utility of epigenetics in the clinic. Our group is in the process of pursuing a larger
ageing study that examines the degree of genome-wide 5mC change with age in a mouse model.
We believe that similar efforts might be underway and along with ours will serve the aging
community to alleviate one of the major problems currently facing the older adult population,
adverse events in pharmacological therapy.
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